Podcasts about google play store

У свіжому дайджесті DOU News обговорюємо появу нового українського deftech єдинорога — компанію UFORCE, та нові правила ППО для критичних підприємств. Розбираємо масштабний реліз від OpenAI: моделі GPT-5.3 Instant та GPT-5.4 Thinking. Також дивіться про приліт по дата-центру AWS, новинки від Apple та рахунок на $82 000 через вкрадений ключ Gemini. Таймкоди 00:00 Інтро 00:26 UFORCE — новий єдиноріг українського дефтеку 03:20 Власна ППО для критичних підприємств 04:34 Курс «AI Engineering» 05:34 Приліт в ОАЕ: дата-центр AWS призупинив роботу 08:45 Падіння Claude: як це вплинуло на розробників 10:44 Розіграш EcoFlow DELTA 3 Max та збори з KOLO 12:05 Google знижує комісію в Play Store до 20% 13:27 Новий інструмент Google для OpenClaw 15:48 Позов проти Google через поради Gemini 18:29 Новинки Apple: MacBook Neo та iPhone 17e 22:43 OpenAI випустила GPT-5.3 Instant 23:15 Реліз моделей GPT-5.4 Thinking та Pro 24:58 Маск програв суд щодо розкриття даних у Каліфорнії 29:14 Позов проти Meta через приватність розумних окулярів 31:09 Крадіжка API-ключа Gemini: рахунок на $82 000 33:30 Що рекомендує Женя: MOMENT // SWARM та BullshitBench Explorer

This week we are joined by Marcelle Lee, cybersecurity consultant and researcher, discussing "CTI tradecraft: Investigating a mobile scareware campaign." She details how a routine click on a Google News story led to a mobile scareware pop-up—and a deeper investigation into a broader campaign. Using free tools like Censys, URLScan, VirusTotal, and CyberChef, she pivoted from two domains to uncover more than 100 related domains, shared infrastructure, and links to questionable antivirus apps in the Google Play Store. The findings are mapped to the MITRE ATT&CK framework, showing how freely available resources can power meaningful, actionable threat intelligence. The research can be found here: ⁠CTI tradecraft: Investigating a mobile scareware campaign Learn more about your ad choices. Visit megaphone.fm/adchoices

This week we are joined by Marcelle Lee, cybersecurity consultant and researcher, discussing "CTI tradecraft: Investigating a mobile scareware campaign." She details how a routine click on a Google News story led to a mobile scareware pop-up—and a deeper investigation into a broader campaign. Using free tools like Censys, URLScan, VirusTotal, and CyberChef, she pivoted from two domains to uncover more than 100 related domains, shared infrastructure, and links to questionable antivirus apps in the Google Play Store. The findings are mapped to the MITRE ATT&CK framework, showing how freely available resources can power meaningful, actionable threat intelligence. The research can be found here: ⁠CTI tradecraft: Investigating a mobile scareware campaign Learn more about your ad choices. Visit megaphone.fm/adchoices

Podcast ONE: 6 de marzo de 2026 CoPaw (IA local sin nube), GPT‑5.4 con millón de tokens, la nueva MacBook Neo “económica”, la guerra Irán‑Israel amplificada por desinformación de IA y todo lo que dejó el #MWC2026. Escucha el nuevo episodio de #PodcastONE en One Digital. Escucha aquí el Podcast ONE: 6 de marzo de 2026 Facebook Live One Digital: CoPaw, GPT-5.4, MacBook Neo y el caos geopolítico de marzo 2026 En este episodio del viernes 6 de marzo de 2026, transmitido en vivo desde São Paulo (Brasil) y Ciudad de México, Vincent Quezada y Pablo Berruecos analizan una semana explosiva: herramientas de inteligencia artificial local (CoPaw), el lanzamiento de GPT‑5.4 con contexto de un millón de tokens, la MacBook Neo (la laptop Apple más económica de su historia), el conflicto geopolítico Irán‑Israel amplificado por desinformación de IA en redes sociales y el Mobile World Congress 2026, que redefinió privacidad, seguridad y conectividad móvil. Un episodio que resume el estado actual de la tecnología, la geopolítica y la ética digital en 2026. ¿Qué es CoPaw? Un agente de IA completamente local sin dependencias en la nube Vincent abre el episodio presentando CoPaw (Co‑Personal Agent Workstation), un agente de inteligencia artificial que funciona completamente en tu equipo local, sin procesar datos en servidores externos como ChatGPT o Gemini. La arquitectura es una evolución directa de los agentes COD (marco multiagente de Alibaba). La diferencia crítica: toda la información permanece dentro de tu máquina, lo que garantiza privacidad total y funcionamiento sin internet una vez instalado el proyecto. “CoPaw no es simplemente un cliente de chat para modelos locales. Es un orquestador de tareas que puede navegar por internet, leer PDFs, generar documentos Word, enviar mensajes por Telegram y ejecutar acciones programadas de forma automática sin intervención humana”. — Vincent Quezada Requisitos técnicos de CoPaw: hardware y software RAM mínima: 8 GB (16 GB ideales para multitarea). Almacenamiento: 10 GB mínimos (20 GB recomendados para modelos grandes). Software: Python 3.10, Node.js v18. GPU opcional pero recomendada: una tarjeta NVIDIA con CUDA acelera respuestas de 15‑40 segundos a 3‑8 segundos. Compatibilidad: Windows, macOS y Linux; la instalación automática gestiona todas las dependencias. Motor de modelos: Ollama (descargable desde ollama.com), disponible para Windows, macOS, Ubuntu y Debian. Modelos de lenguaje local según necesidad y RAM disponible La elección del modelo depende de tu hardware y de tu caso de uso. Vincent explica que el número al final del nombre (3B, 7B, 8B, 14B) representa los miles de millones de parámetros que maneja; a mayor número, mayor precisión, pero también más RAM requerida. Phi 3 Mini (4 GB RAM): respuestas cortas, equipos básicos, uso introductorio. Llama 2 8B (8 GB RAM): velocidad media (15‑40 segundos), ideal para redacción general, análisis de textos y resúmenes. Mistral 7B (8 GB RAM): especializado en escritura creativa y resúmenes de contenido largo. DeepSeek 8B (8 GB RAM): razonamiento lógico, análisis de código y debugging. Qwen 3 (14B) (16 GB RAM): tareas complejas y análisis extenso de datos; es lento sin GPU. “No uses un modelo de 20 gigabytes para una simple traducción. Es como manejar un camión de carga para ir a la tienda. Elige según tu tarea real”. — Vincent Quezada Módulos especializados que llevan CoPaw más allá del chat básico CoPaw incluye módulos independientes que se activan automáticamente según el contexto de tu tarea. Cada uno requiere cierta configuración específica. Browser Reissable: navegador web autónomo que busca información en tiempo real; requiere la instalación de Playwright. News Module: búsqueda y resumen automático de noticias; requiere una clave API de Tavily (gratuita con 1,000 búsquedas mensuales). File Reader: lee archivos locales (.txt, .csv, .json) sin configuración adicional. PDF Module: extrae, analiza y resume PDFs complejos. DOCX Module: crea y edita documentos Word de forma automática. XLSX Module: manipula hojas de cálculo y calcula promedios, máximos y mínimos de columnas. PPTX Module: genera presentaciones de PowerPoint de forma automática. Cron Jobs (automatización): programa tareas para ejecutarse en intervalos específicos (diarios, semanales, cada N horas) sin intervención del usuario. Email Manager (Himalaya): gestión automática de correos; Vincent lo recomienda solo para usuarios avanzados. Casos de uso prácticos según nivel de experiencia Principiante: “Busca las noticias más importantes de inteligencia artificial de hoy”. “Explica la diferencia entre aprendizaje autónomo y aprendizaje profundo con ejemplos prácticos”. “Redacta un correo formal para solicitar una reunión con un cliente importante”. Intermedio: “Lee el archivo C:UsuariosDocumentosreporte.pdf y genera un resumen ejecutivo de máximo 500 palabras”. “Abre ventas_2025.xlsx, identifica los tres meses con mayor crecimiento entre enero y marzo y muestra los porcentajes”. “Navega a Amazon.com.mx, busca auriculares inalámbricos menores a 1,500 pesos y lista las cinco mejores opciones con precio y enlace”. Avanzado: “Busca las cinco noticias tecnológicas más importantes de hoy, redacta un párrafo de 150 palabras para cada una y guarda el resultado en noticiashoy.docx”. “Lee todos los archivos .csv de C:datos, combínalos en uno solo y calcula el promedio, máximo y mínimo de cada columna numérica”. “Navega a LinkedIn, busca vacantes de redactor de contenido publicadas esta semana en Ciudad de México, extrae títulos, empresas, enlaces y guarda todo en empleos.xlsx”. Automatización con tareas programadas: el verdadero diferenciador de CoPaw La función más poderosa es la capacidad de programar ejecuciones automáticas sin que el usuario esté presente. Esto convierte a CoPaw de una simple herramienta de chat en un asistente de productividad genuino. Resumen diario de noticias: “Configura una tarea que se ejecute todos los días a las 8:00 a. m.: busca las principales noticias de tecnología e IA y guarda el resultado en noticiasdiarias.txt”. Monitoreo de precio de criptomonedas: “Crea una tarea cada seis horas: registra la cotización actual de Bitcoin con fecha y hora en precio.txt”. Reporte semanal consolidado: “Programa una tarea cada lunes a las 9:00 a. m.: lee todos los archivos .txt de C:reportes, genera un resumen ejecutivo y guarda el documento como reportesemanal.docx”. Limpieza automática de archivos: “Configura una tarea cada viernes a las 11:00 p. m.: mueve todos los archivos .log con más de 30 días de antigüedad a la carpeta archivos_antiguos”. Estas variables (frecuencia, horarios, tiempos de latido o heartbeat) se controlan en el archivo config.json. Vincent subraya la importancia de probar con cuidado antes de automatizar procesos críticos. ¿CoPaw requiere internet? Solución de errores comunes CoPaw funciona completamente sin conexión una vez instalado con su modelo descargado. Solo requiere internet para búsquedas web mediante Tavily y si configuras APIs externas (OpenAI, Anthropic). Los errores más frecuentes que Vincent encontró durante sus pruebas son: “No es posible conectar con servidor CoPaw”: verifica que ejecutaste copaw start y que el puerto 8088 está disponible. “Comando copaw no reconocido”: el directorio de ejecución no está en el PATH del sistema; asigna la ruta manualmente o usa el script completo. “Ollama no disponible”: la dirección debe ser exactamente localhost:11434 sin sufijos; revisa el archivo de configuración. CoPaw vs. OpenCloud: ¿cuál es mejor? “CoPaw fue más útil que OpenCloud en mis pruebas. Mientras OpenCloud es muy potente, CoPaw ofrece instalación más rápida, una interfaz más accesible y documentación más clara. Ambas son de código abierto bajo licencia Apache 2.0. CoPaw es completamente gratis; solo la clave de Tavily tiene un costo opcional (unos 10 dólares mensuales)”. — Vincent Quezada MacBook Neo: la primera laptop Apple verdaderamente económica (599 dólares) Apple lanzó la MacBook Neo, un quiebre histórico en su estrategia de precios. Por primera vez en la historia de Macintosh existe una laptop Apple genuinamente accesible: 599 dólares (499 dólares para educación). Dirigida a estudiantes y nuevos usuarios, representa un cambio radical en la democratización del ecosistema Apple. Especificaciones técnicas de la MacBook Neo Procesador: chip A18 Pro; seis núcleos (dos de rendimiento y cuatro de eficiencia); GPU de cinco núcleos; Neural Engine de seis núcleos para tareas de inteligencia artificial. Rendimiento en IA: hasta tres veces más rápido en cargas de trabajo de inteligencia artificial que la competencia; acceso completo a Apple Intelligence manteniendo la privacidad de los datos. Pantalla Liquid Retina: 13 pulgadas, 2,408 × 1,506 píxeles, 510 nits de brillo, soporte para mil millones de colores; una de las pantallas más brillantes en su rango de precio. Batería: 36,5 Wh, hasta 16 horas de autonomía en uso mixto; dos puertos USB‑C para carga rápida. Diseño y construcción: carcasa de aluminio resistente, peso de solo 1,23 kg; colores disponibles: Blush, Indigo, Plata y Eléctrico. Conectividad: Wi‑Fi 6E, Bluetooth 6, entrada de audio de 3,5 mm (rara hoy en día), cámara FaceTime HD 1080p, micrófono dual y audio espacial Dolby Atmos. Almacenamiento: 256 GB base (Vincent cuestiona esta especificación a ese precio, pues alternativas con Windows ofrecen 512 GB por menos dinero). Software: macOS preinstalado con integración completa de Apple Intelligence. Disponibilidad: envíos a partir del 11 de marzo de 2026. “La pantalla es realmente excepcional. Es una de las mejores que he visto comparada con iPads y monitores tradicionales. Solo por ese aspecto la MacBook Neo se justifica”. — Vincent Quezada ¿Para quién es la MacBook Neo? Estudiantes: necesitan un equipo potente, ligero y con batería para todo el día; el precio educativo (499 dólares) es especialmente atractivo. Nuevos usuarios de Mac: quienes buscan una introducción asequible al ecosistema Apple sin gastar más de 1,200 dólares. Profesionales de tareas cotidianas: navegación web, edición de documentos, videollamadas y productividad básica. Usuarios preocupados por la sostenibilidad: está fabricada con un 60% de material reciclado. Vincent lanza una advertencia: el almacenamiento base de 256 GB a 599 dólares es cuestionable, ya que por ese mismo precio se encuentran laptops Windows con 512 GB que ofrecen mejor valor a corto plazo. Sin embargo, el diseño, la pantalla y la autonomía de la MacBook Neo compiten favorablemente. GPT‑5.4 de OpenAI: millón de tokens, automatización y 33% menos errores OpenAI lanzó GPT‑5.4 el 5 de marzo de 2026, apenas un día antes de este episodio. Durante la conversación, ChatGPT (participando en diálogo con Vincent) explicó las novedades clave que marcan diferencia en el mercado: contexto de hasta un millón de tokens, mejora del 33% en reducción de errores respecto a la versión previa, herramientas de automatización más profundas y mayor integración con flujos de trabajo profesionales. (Los detalles técnicos completos se abordan con más calma en el programa, pero el foco del episodio está en el impacto práctico y geopolítico.) Irán ataca infraestructura crítica: desinformación de IA amplifica el caos geopolítico A mitad del episodio, la conversación gira hacia el conflicto que explota sobre el planeta: Irán lanzó ataques contra bases militares estadounidenses, centros de datos (incluyendo instalaciones de Microsoft Azure en el Golfo Pérsico) y sistemas de desalinización en Oriente Medio. Vincent y Pablo enmarcan este escalamiento dentro de una historia más amplia: Estados Unidos, en apenas 250 años de existencia, ha estado en paz solo 16 años; el resto ha sido conflicto bélico constante. Irán, durante cuatro décadas, ha acumulado una capacidad defensiva nacional inmensa. Cuando se lanzan misiles de un millón de dólares para destruir drones de 20,000 dólares, la economía de la guerra revela su irracionalidad inherente. “Estamos viendo una operación quirúrgica de un país que lleva décadas preparándose para un momento así. No es improvisado; es cálculo estratégico. El problema es que genera nacionalismo extremo, no revolución interna”. — Vincent Quezada ¿Cuántos países están realmente involucrados? Expansión del conflicto más allá de Irán e Israel Lo que inicialmente parecía ser un conflicto bilateral Irán‑Israel se ha expandido a entre 16 y 17 países. No se trata solo de ataques entre naciones, sino también de: Ataques a bases militares de Estados Unidos en múltiples naciones del Golfo Pérsico. Infraestructura civil crítica comprometida, como plantas desalinizadoras que suministran agua a millones de personas. Centros de datos de Microsoft Azure, que gestionan sistemas de la OTAN, la defensa estadounidense y grandes instituciones financieras. Sistemas GPS degradados o bloqueados en las zonas del conflicto. Pablo subraya que una planta desalinizadora comprometida en el Golfo Pérsico afecta a millones de civiles. No se trata solo de un conflicto militar, sino de un ataque sistémico a la supervivencia civil. “La estrategia inicial que leí era que, después de matar al líder, habría revolución interna y cambio de gobierno. No funciona así. No puedes cambiar 40 años de dominación, creencia popular y cultura con un bombardeo. Generó nacionalismo extremo, justo lo contrario”. — Pablo Berruecos Gasto económico diario: más de mil millones de dólares en conflicto activo La cifra de gasto militar diario es casi incomprensible. Según el monitoreo de cuentas en X (Twitter) que rastrean gasto militar en tiempo real, el conflicto cuesta más de mil millones de dólares al día. Comparado con las pérdidas bursátiles simultáneas en Estados Unidos (Nvidia ‑1,55%, Google en rojo, Apple ‑1,42%, Visa ‑0,69%, Amazon ‑0,48%, Tesla ‑2,33%), el costo económico global es catastrófico. Desglose de los primeros días de ataques Día 1 (primer ataque de Irán): 500 misiles lanzados hacia Israel y bases estadounidenses. Día 2: 200 misiles. Día 3: 100 misiles. Día 4: 50 misiles. Día 5 y posteriores: 15‑20 misiles, pero con intensificación del uso de drones y sistemas más sofisticados. En cuanto a municiones, para interceptar cada misil lanzado Estados Unidos empleó entre 10 y 20 misiles Tomahawk, cuyo coste ronda los 4‑5 millones de dólares cada uno. La matemática es devastadora: para defenderse de 500 misiles, se gastaron entre 5,000 y 10,000 millones de dólares solo en defensa. Irán, con un presupuesto militar inferior, amplifica su impacto usando drones de bajo coste que replican la capacidad de misiles mucho más caros. ¿Por qué Dubái está en pánico? Crisis de confianza en los paraísos fiscales Pablo narra una anécdota inquietante: una influencer española se mudó a Dubái explícitamente para no pagar impuestos. Cuando comenzó el bombardeo, pidió al gobierno español que la rescatara. Las redes sociales reaccionaron con dureza: “Te fuiste para evitar impuestos, pero esperas que nuestros impuestos te salven”. Más allá del drama mediático, esto revela una crisis de confianza más profunda. Dubái representa la opulencia extrema (albercas en cada piso, derroche de dinero). Al mismo tiempo es una ciudad vulnerable: construida en medio del desierto sin recursos naturales, depende de agua desalinizada y petróleo importado. Una planta desalinizadora comprometida deja a millones de personas sin acceso a agua potable. Las embajadas no pueden evacuar a todos; la capacidad del aeropuerto es limitada. Los depósitos de oro de países del Golfo plantean preguntas: ¿quién los controla si hay invasión? ¿Se pierde la credibilidad de esa moneda? “Dubái te da una ilusión de seguridad. Luego descubres que estás tan vulnerable como en cualquier otro sitio. Si pierdes acceso a agua, dinero y energía, la opulencia desaparece en cuestión de horas”. — Pablo Berruecos ¿Es una tercera guerra mundial? La respuesta compleja de Vincent y Pablo La gran pregunta: ¿es esto la tercera guerra mundial? Vincent y Pablo responden que no, pero sí se trata de un conflicto multinacional sin precedentes recientes. Factores que empujan hacia un conflicto total: múltiples frentes (tecnológico, energético, cibernético), riesgo de escalamiento incalculable y poder nuclear en equilibrio inestable. Factores limitantes: China no quiere involucrarse (si lo hace, el “game over” planetario); Rusia comenta desde la banda; la diplomacia existe, pero parece ficción. Realidad actual: es una guerra sin declaración formal, sin límites claros y sin un final visible. Es un conflicto mayor que podría convertirse en guerra mundial si alguien toma la decisión equivocada. Censura en redes sociales: TikTok, Grok y ChatGPT eliminan realidad selectivamente Vincent lanza una acusación central: las plataformas de redes sociales están censurando el conflicto real mientras amplifican la desinformación generada con IA. Se forma así un mecanismo de control dual. Censura selectiva. TikTok, Grok y ChatGPT han censurado términos como “Palestina libre”, bloquean videos de ataques verificables y silencian reportajes de bombardeos reales. El resultado es que los usuarios no ven la magnitud real del conflicto. Amplificación de desinformación. Al mismo tiempo, videos falsos generados con IA se replican masivamente. Un ejemplo documentado es un video de un misil impactando un portaaviones, con barcos salvavidas saliendo disparados de forma físicamente imposible. Medios internacionales lo replicaron como si fuera un evento real. “Mucha gente salió de ChatGPT esta semana no por problemas técnicos, sino porque OpenAI dijo ‘sí' a participar en la guerra cuando Anthropic dijo ‘no'. Unos 1,5 millones de usuarios migraron por cuestiones éticas”. — Vincent Quezada El parque “Policía” de Teherán: cómo la IA comete atrocidades sin intención Un detalle sintetiza la tragedia: en Teherán existe un parque público llamado Parque Policía. Sistemas de IA estadounidenses lo detectaron como “base militar de policía” y lo bombardearon. No había policías, solo civiles. Se destruyó infraestructura pública sin valor militar. Esto ilustra una crisis existencial: si los sistemas de IA se usan para identificar blancos y esos sistemas cometen errores de clasificación, ¿quién es responsable? La respuesta legal suele ser que nadie, porque “fue una máquina”. El patrón se repite: Hospitales destruidos. Escuelas destruidas. Iglesias destruidas. Cada error (Con o sin intención) se traduce en más víctimas civiles. ¿Qué porcentaje de lo que ves es real y qué parte es generado por IA? Esta es la pregunta que obsesiona a Pablo al final de la sección. En redes sociales, el feed está contaminado: videos viejos del año pasado, videos recientes manipulados con IA, análisis en tiempo real legítimos, campañas de desinformación coordinada y censura selectiva, todo mezclado. Pablo cita un reportaje de un canal europeo (disponible vía Roku) que analizaba la cantidad masiva de videos falsos que circulan. La conclusión es aterradora: no sabes en qué creer. “Entre no ver nada (porque está censurado) y ver todo falso (porque es IA), terminas paralizado. La verdad deja de importar cuando ya no sabes identificarla”. — Pablo Berruecos Impacto tecnológico real: Microsoft Azure y la columna vertebral digital del conflicto Un detalle merece su propio análisis: Irán atacó centros de datos de Microsoft en el Golfo Pérsico. No se trata de servicios comerciales como AWS, sino de infraestructura Azure que soporta: La columna vertebral operativa de la OTAN. El Departamento de Defensa de Estados Unidos. Grandes instituciones financieras occidentales. Infraestructura militar 5G. Zonas de disponibilidad Azure con clasificación FedRAMP High, la más alta que puede obtener un proveedor comercial. Si estos centros de datos llegaran a caer (algo aún no confirmado oficialmente), el impacto sería catastrófico para la estructura de defensa y las finanzas occidentales. Pablo subraya que esto no es un ataque comercial, sino un ataque al tejido conectivo digital que une la arquitectura de defensa con las ambiciones soberanas de IA en el Golfo Pérsico. Conclusión parcial. El conflicto Irán‑EU – Israel ya no es solo militar; es digital, económico y tecnológico. La desinformación generada con IA amplifica el caos mientras la censura selectiva paraliza la comprensión pública. El resultado es un planeta sin ley en el que la verdad es tan escasa como la paz. Mobile World Congress 2026: privacidad, seguridad y conectividad satelital Tras el análisis geopolítico, Vincent y Pablo redirigen la conversación hacia el Mobile World Congress 2026 en Barcelona, el evento más importante de la industria móvil global. Este año marca un punto de inflexión: privacidad y seguridad dejan de ser características opcionales para convertirse en pilares competitivos. Motorola abandona el Android tradicional por GrapheneOS; múltiples fabricantes lanzan teléfonos con Linux exclusivos para Europa; MediaTek integra conectividad satelital 5G; Nothing presenta el Phone 4 con diseño transparente Glyph Matrix. Pablo y Vincent diseccionan cada lanzamiento con detalle técnico. Nothing Phone 4: diseño Glyph Matrix transparente Nothing lanzó el Phone 4 con una propuesta radical: mantener el diseño transparente icónico y añadir Glyph Matrix, una matriz de 137,000 mini‑LEDs que cubren el 57% de la parte trasera del dispositivo y que brillan un 100% más que en generaciones anteriores. Estos LEDs generan iconos personalizables (batería, temporizador, reloj digital, espejo Glyph, camino solar) que transforman la cámara trasera en una interfaz háptica y visual única. Especificaciones técnicas del Nothing Phone 4 Diseño Glyph Lift Matrix: fusión de un cuerpo unibody de metal con refracciones de luz, acabados suaves sin fisuras y un diseño retrofuturista inspirado en cámaras de cine vintage y consolas clásicas. Colores: plata, negro y rosa metálico (poco común en 2026 y distintivo a simple vista). Cámara trasera principal: sensor Sony Exmor 700c de gran tamaño, 50 megapíxeles, zoom óptico 3,5x. Cámara gran angular: sensor Sony de 32 megapíxeles para captura de contexto amplio. Motor Lens Engine 4: compatible con fotos y video 4K Ultra HDR, efectos HDR Flex y Dolby Vision integrado. Pantalla AMOLED de 6,83 pulgadas: resolución 1,5K (2,408 × 1,506 píxeles), 450 ppp, tasa de refresco de 144 Hz (ideal para videojuegos) y brillo máximo de 5,000 nits. Protección: cristal Corning Gorilla Glass 7i con resistencia mejorada a caídas y rasguños. Procesador: Snapdragon 7 Serie Gen 4; CPU un 27% más rápida y GPU un 30% más potente que la generación anterior; capacidades de IA un 65% superiores. Memoria y almacenamiento: RAM LPDDR5X y almacenamiento UFS 3.1, con velocidades de lectura y escritura elevadas. Batería: 5,080 mAh, carga rápida de 50 W y más de 17 horas documentadas de uso mixto. Software: Nothing OS 4.1 basado en Android 16, con AI Dashboard para control de funciones de IA, Essential AI para organización de calendario y vida diaria, Essential Search (acceso multiplataforma inmediato), Essential Memory (personalización según actividad), Playground (creación de apps sin código) y Essential Space (sincronización en la nube multiplataforma). Precio y disponibilidad: la revelación oficial se programa para el 18 de marzo de 2026. Vincent confirma invitación al evento, pero con conflicto de agenda; espera recibir unidades de prueba. “El diseño transparente de Nothing no es solo estética; es filosofía. Muestran lo que todas las demás marcas ocultan. Es una declaración sobre privacidad y accesibilidad”. — Vincent Quezada Pruebas de cámara con el Honor Magic 8 Lite Vincent comparte sus pruebas de cámara con el Honor Magic 8 Lite realizadas durante un fin de semana en Chapultepec (Ciudad de México). Sus conclusiones son claras: la fotografía es excelente, el video es aceptable pero presenta limitaciones de estabilización al usar el zoom máximo. La batería del Honor duró desde el domingo hasta el viernes con un 82% restante al momento de grabar, algo que Vincent califica de “maravilla” frente a la competencia. La carga rápida también impresiona: del 15% al 80% en menos de 30 minutos. MediaTek M90: primer chip 5G con conectividad satelital integrada MediaTek presentó el M90, el primer chip móvil 5G con conectividad satelital integrada de fábrica. Esto permite que los dispositivos accedan a redes como Starlink Mobile incluso sin infraestructura celular terrestre. En contextos críticos —terremotos, conflictos armados, zonas rurales remotas—, esta conectividad híbrida 5G‑satelital es infraestructura de supervivencia, no un lujo tecnológico. ¿Por qué la conectividad satelital es crítica? Vincent comparte evidencia directa: durante simulacros de alerta sísmica y terremotos reales de 2026 en México, solo dos de sus cuatro teléfonos recibieron la alerta de emergencia. Los que tenían Wi‑Fi permanente activo y chips compatibles con conectividad satelital sí captaron la señal; los otros, no. La conclusión es inequívoca: la redundancia de conectividad puede literalmente salvar vidas. Casos de uso estratégicos: comunicaciones militares sin depender de operadores civiles comprometidos, navegación precisa en regiones sin torres celulares, transmisión de datos en vehículos autónomos en autopistas remotas y alertas de emergencia en zonas sísmicas o bajo ataque. Implicación geopolítica: gobiernos y fuerzas de seguridad pueden operar de forma independiente a los monopolios de conectividad nacional y los ciudadanos en zonas de conflicto pueden comunicarse sin censura de proveedores locales. Velocidad: no es la más alta (la latencia es mayor que la del 5G terrestre), pero garantiza conectividad donde no hay alternativas viables. “La conectividad satelital no es un lujo; es infraestructura crítica de supervivencia. Si no recibiste la alerta sísmica porque tu teléfono no tenía redundancia, la tecnología fracasó”. — Vincent Quezada Motorola abandona Android tradicional: apuesta por GrapheneOS Motorola anunció oficialmente el fin de su línea de dispositivos con Android estándar y su migración hacia GrapheneOS, un sistema operativo de código cerrado pero obsesionado con la privacidad. GrapheneOS implementa un aislamiento extremo a nivel granular: una aplicación de mensajería no puede acceder a micrófono, cámara o ubicación a menos que el usuario lo autorice explícitamente en cada sesión. Esta decisión responde a una demanda corporativa creciente de teléfonos resistentes a la vigilancia masiva, a ciberataques y a la exfiltración de datos. El mercado objetivo son empresas multinacionales, gobiernos, periodistas en contextos de riesgo y usuarios muy conscientes de la privacidad. Ventajas de GrapheneOS: aislamiento estricto por aplicación, permisos granulares que expiran por sesión, resistencia a puertas traseras corporativas o gubernamentales y actualizaciones de seguridad más rápidas que en Android AOSP. Desventajas: fragmentación de aplicaciones, compatibilidad limitada con Google Play Services, ecosistema menos maduro y curva de aprendizaje más pronunciada para usuarios no técnicos. Precio estimado: no se ha revelado oficialmente, pero se espera un sobreprecio de entre el 15% y el 20% respecto a modelos Android estándar. “Android abierto es poderoso pero vulnerable. GrapheneOS es Android cerrado, paranoico y centrado en la privacidad. La elección depende de si valoras más la conveniencia o el control absoluto de tus datos”. — Pablo Berruecos Teléfonos con Linux: código abierto verificable y seguridad auditada Varios fabricantes presentaron prototipos de teléfonos basados completamente en Linux, con lanzamiento inicial exclusivo en Europa. Linux ofrece transparencia total de código fuente, auditoría comunitaria constante y resistencia natural a puertas traseras corporativas o gubernamentales. Aunque el mercado se limita, de momento, a Europa por las estrictas regulaciones del RGPD, las proyecciones apuntan a una expansión global alrededor de 2027. Ventaja clave: código abierto 100% verificable, auditoría de seguridad comunitaria permanente, ausencia de telemetría corporativa oculta y actualizaciones controladas por el usuario. Desafío principal: enorme fragmentación de aplicaciones, compatibilidad casi nula con Google Play Store, ecosistema de apps menos maduro e interfaces menos pulidas que Android o iOS. Público objetivo: gobiernos europeos con requisitos de soberanía digital, periodistas de investigación, disidentes políticos y profesionales de sectores de seguridad crítica (finanzas, defensa, salud). Otros lanzamientos destacados del Mobile World Congress 2026 Smartphones con innovación radical en diseño y modularidad Honor Robot Phone: cámara de 200 megapíxeles montada en un brazo gimbal motorizado que se despliega desde el chasis, permitiendo ángulos de captura profesionales imposibles en teléfonos convencionales (autorretratos sin distorsión, videografía con estabilización tipo cine, panorámicas sin cortes digitales). Motorola Razr y Edge (FIFA World Cup 26 Collection): ediciones especiales con logotipo oficial del torneo, interfaz personalizada del evento y colores temáticos. Xiaomi 17 Ultra: presentación europea con especificaciones de gama alta, precio por anunciar pero competitivo frente al Samsung Galaxy S26 Ultra. Nothing Phone 4A: versión más accesible del Phone 4 con colores llamativos (destaca el rosa metálico) y un Glyph Matrix reducido pero funcional. Unihertz Titan Elite 2: teclado físico completo (nostalgia BlackBerry) en un formato moderno con Android 16. Vivo X300 Ultra: cámara de 200 megapíxeles y lanzamiento global fuera de China, la primera vez que Vivo lleva un buque insignia de este tipo a mercados occidentales. Tecno Atom (modular magnético): sistema de accesorios magnéticos intercambiables inspirado en los antiguos Moto Mods (proyectores, cámaras adicionales, baterías extendidas) sin sacrificar portabilidad diaria. Tecno Power Neon: incorpora iluminación neón real usando tecnología de gas inerte de baja tensión; diseño retrofuturista cyberpunk; primer teléfono con neón físico desde 2003. Legion Gold Fold (concepto): teléfono plegable centrado en videojuegos, con pantalla de 240 Hz y gatillos ultrasónicos integrados. Laptops y tablets con pantallas modulares e IA integrada Lenovo ThinkBook módulo IPC: puertos intercambiables magnéticos para conectar una segunda pantalla portátil; extensión dinámica del espacio de trabajo sin cables. Lenovo Yoga Book Pro D: doble pantalla con visualización 3D sin necesidad de gafas de realidad virtual, productividad multitarea reforzada y reconocimiento de gestos en el aire. Asus VivoBook Pad XPS: tablet estilo laptop con pantalla OLED más grande (15,6 pulgadas) y teclado mecánico desmontable mejorado. Chips y conectividad avanzada: preparación para 6G Qualcomm FastConnect 8800: módulo Wi‑Fi 7 con IA integrada para optimizar el ancho de banda automáticamente según el tipo de contenido. Qualcomm X105 5G: módem un 15% más rápido, un 20% más pequeño y un 30% más eficiente que el X100, pensado como puente hacia 5G Advanced (5G‑A). Snapdragon Wear Elite: chip orientado a wearables y robótica, con procesamiento de baja latencia (por debajo de 10 ms), ideal para relojes inteligentes, audífonos con IA y robots de servicio. Samsung y la pantalla anti‑espionaje Samsung presentó una tecnología de pantalla que impide que las personas situadas a los lados del usuario vean el contenido. La innovación cambia la forma en que los píxeles emiten luz: se coloca un “aro óptico” alrededor de cada píxel que nubla la imagen cuando se observa desde ángulos laterales. Desde el frente, la imagen es perfectamente clara; desde cualquier otro ángulo, se ve borrosa e ilegible. “Esto resuelve el problema de privacidad en transporte público, oficinas compartidas y aeropuertos. Finalmente puedes trabajar con información sensible sin preocuparte de quién mira por encima de tu hombro”. — Pablo Berruecos Conclusión parcial. El Mobile World Congress 2026 consolidó privacidad, seguridad y conectividad satelital como pilares no negociables de la telefonía móvil. Nothing Phone 4 democratiza el diseño transparente; MediaTek integra satelital en chips 5G; Motorola apuesta por GrapheneOS; Europa lidera con teléfonos Linux. La pregunta ya no es “qué tan rápido es tu teléfono”, sino “qué tan privado y resiliente es”. Robots humanoides y audífonos inteligentes: la IA se vuelve física El Mobile World Congress 2026 no giró solo en torno a teléfonos. La inteligencia artificial se materializó en hardware físico: robots humanoides capaces de bailar moonwalk, audífonos que analizan la geometría del canal auditivo para prevenir pérdida de audición, dispositivos para mascotas con llamadas bidireccionales mediante gestos y gafas de realidad extendida con traducción en tiempo real. Vincent y Pablo exploran estas innovaciones con mirada crítica. Honor Robot Humanoid: bípedo capaz de bailar y servir Honor presentó un robot humanoide bípedo completamente funcional, capaz de bailar (incluyendo un moonwalk que se volvió viral), mantener el equilibrio en superficies irregulares y ejecutar tareas de servicio básicas. Pablo recuerda un momento particularmente comentado: un robot humanoide propinando un “golpe bajo” a un boxeador durante una demostración, probablemente por un error de calibración, que generó memes instantáneos. Capacidades motoras: caminar de forma estable, correr a baja velocidad, subir escaleras y bailar coreografías preprogramadas. Casos de uso previstos: servicio hotelero, asistencia en hospitales, limpieza industrial y entretenimiento en eventos. Limitaciones actuales: velocidad de procesamiento de IA para decisiones complejas, autonomía de batería de entre cuatro y seis horas en operación continua y costo prohibitivo para el consumidor final (por encima de 50,000 dólares). PetFoam: comunicación bidireccional para mascotas PetFoam es un dispositivo que permite a las mascotas “llamar” a sus dueños mediante gestos reconocidos por IA. Por ejemplo, un perro que rasca un sensor específico puede activar una videollamada al dueño. Este, a su vez, puede responder con voz, mientras la mascota ve la imagen en una pequeña pantalla integrada. El caso de uso central es claro: mascotas en una posible emergencia (heridas, atrapadas) pueden alertar sin que haya intervención directa de otra persona. Google Iris XR: gafas de realidad extendida con traducción simultánea Google presentó el prototipo Iris XR, unas gafas de realidad extendida —no realidad virtual completa— con traducción en tiempo real integrada mediante IA. Sus casos de uso incluyen viajes internacionales, reuniones multilingües y accesibilidad para personas sordas (con subtítulos en tiempo real de las conversaciones). De momento no tienen fecha de lanzamiento comercial y solo están disponibles en demos controladas del MWC. Audífonos inteligentes que analizan tu oído: riesgos y beneficios Los audífonos evolucionan de meros accesorios pasivos a dispositivos de bioacústica avanzada. En el MWC 2026 se mostraron modelos capaces de analizar la geometría única del canal auditivo del usuario para ajustar de forma dinámica la cancelación de ruido, la ecualización personalizada y la exposición a decibeles. Esto crea un perfil acústico único por oído, minimizando la fatiga auditiva acumulativa y el riesgo de pérdida de audición permanente. Características técnicas de estos audífonos Cancelación de ruido adaptativa: detecta frecuencias específicas del entorno (motor de autobús, viento, multitudes, maquinaria industrial) y las atenúa selectivamente sin aislar por completo. Medición de decibeles en tiempo real: emite alertas visuales o hápticas si el volumen excede los 85 dB durante más de 30 minutos, siguiendo el límite seguro sugerido por la OMS. Análisis de la forma del oído: ajusta la presión en el canal auditivo y modifica el ancho de banda según la morfología individual, reduciendo la fatiga en usos prolongados de más de ocho horas diarias. Ecualización personalizada: compensa las deficiencias auditivas naturales de cada usuario en determinadas frecuencias. Riesgos para la salud auditiva: la presión en el tubo de Eustaquio Vincent advierte sobre un riesgo poco mencionado por los fabricantes: la cancelación de ruido total crea un sello hermético que genera presión en el canal auditivo. Esta presión activa el tubo de Eustaquio, responsable de regular la presión en el oído medio. El uso prolongado con sellado hermético puede: Comprometer la capacidad natural del oído para regular la presión (similar a lo que ocurre en un avión). Crear dependencia de una presión artificial para “escuchar correctamente”. Generar fatiga auditiva acumulativa por exceso de vibraciones internas. Aumentar el riesgo de infecciones de oído medio por retención de humedad. “La cancelación de ruido total te aísla del mundo. Una cancelación inteligente te mantiene conectado a tu entorno mientras disfrutas la música. La diferencia es literal entre la vida y un accidente”. — Vincent Quezada Caso práctico en Chapultepec: ceguera auditiva y casi choque Pablo cuenta una experiencia personal: caminaba en Chapultepec, en Ciudad de México, con audífonos con cancelación activa total. No escuchó a una persona que le gritaba para evitar un choque. Cuando finalmente la vio, ya era tarde y terminaron chocando. Reflexiona que, si hubiera estado en bicicleta y no escuchara la campanilla del trenecito turístico —que avisa su paso—, podría haber frenado de golpe y causar un accidente. Su recomendación es clara: nunca uses cancelación de ruido total en espacios públicos como calles, ciclovías o transporte. Actívala solo en entornos controlados y seguros (oficina, casa, avión). Mantén siempre un nivel medio de cancelación que permita escuchar alertas críticas del entorno (claxon, sirenas, gritos de advertencia). “Tengan cuidado. Si vas en el camión o en transporte público y te toca sentarte atrás del motor, el ruido se vuelve insoportable. Los filtros te dejan solo con la música y con el entorno realmente importante. Pero si te aíslas por completo, no sabes si alguien te está alertando de un peligro real”. — Pablo Berruecos Alianzas estratégicas hacia 6G: Nokia, NTT, Vodafone y más El MWC 2026 no solo presentó dispositivos, sino alianzas estratégicas que definen la ruta hacia un 6G nativo en inteligencia artificial. Nokia, NVIDIA, NTT, NTT Docomo, Vodafone, BT, Elisa y otros operadores anunciaron colaboraciones para adoptar tecnologías AI‑RAN (inteligencia artificial en redes de acceso radio) que mejoran el rendimiento de la red y soportan el crecimiento exponencial de la IA móvil. ¿Qué es 6G y cuándo llegará? Vincent y Pablo aclaran una confusión común: 5G Advanced (5G‑A) no es una nueva generación, sino un refinamiento del 5G existente con más velocidad, menor latencia y mejor eficiencia energética. El verdadero salto generacional será 6G, proyectado para 2030‑2032 según el consenso de los operadores presentes en el MWC. Características esperadas de 6G: velocidades teóricas 100 veces más rápidas que 5G (hasta 1 Tbps), latencias de menos de 0,1 ms (frente a 1 ms en 5G), conectividad híbrida 5G‑satelital como estándar, orquestación de IA de forma nativa en la red y uso de fotónica óptica para reducir el consumo energético. Infraestructura necesaria: inversión estimada de 100,000 millones de euros a nivel global, renovación completa de torres celulares e integración de computación cuántica en los núcleos de red. Casos de uso diferenciales: vehículos autónomos de nivel 5 (sin intervención humana), cirugías remotas en tiempo real con robótica, realidad extendida persistente (un metaverso funcional) y ciudades inteligentes con millones de sensores de IoT sincronizados. “6G no será mejor solo por ser 6G. Será mejor porque será inteligente, consciente del contexto y capaz de auto‑optimizarse en tiempo real sin intervención humana”. — Vincent Quezada Financiamiento y fotónica óptica: la apuesta de NTT Group AWS anunció la expansión de su infraestructura en mercados emergentes (India, Indonesia, Nigeria). Vodafone, la GSMA y otros organismos de telecomunicaciones aseguraron financiamiento de hasta 100 millones de euros específicamente para el desarrollo de estándares 6G con IA integrada desde el diseño. Esta inversión señala un cambio: actores privados financian estándares que antes estaban bajo control casi exclusivo de gobiernos. Por su parte, NTT Group (Japón) presentó sus avances en fotónica óptica y redes ópticas inalámbricas (ION: Innovative Optical and Wireless Network). El objetivo es reducir el consumo energético de los centros de datos, disparado por el uso intensivo de inteligencia artificial. Entre los proyectos destacados se encuentran: Convergencia fotónico‑electrónica: mejora la eficiencia energética de los centros de datos hasta un 60% respecto a la electrónica tradicional. Computación cuántica óptica: cálculos a gran escala con menor espacio físico, más velocidad y menores costes a largo plazo. Infraestructura resiliente con IA: redes autorreparables que detectan y resuelven fallos sin intervención humana. Ya no se trata solo de lanzar productos, sino de redefinir cómo se integran telecomunicaciones, movilidad y tecnología para sostener la explosión de la IA sin colapsar redes eléctricas a nivel global. Conclusión general: hacia una tecnología más consciente El episodio del 6 de marzo de 2026 captura un momento bisagra. La inteligencia artificial local (CoPaw) permite privacidad sin sacrificar productividad; GPT‑5.4 amplía el contexto a niveles impensables hace apenas un año; la MacBook Neo democratiza el acceso a macOS; el conflicto Irán‑Israel muestra cómo la desinformación generada por IA paraliza la comprensión pública mientras la censura selectiva oculta la realidad; y el Mobile World Congress 2026 consagra la privacidad, la seguridad satelital y el 6G como pilares del futuro móvil. Motorola abandona Android por GrapheneOS. Llegan teléfonos con Linux a Europa. MediaTek integra la conectividad satelital en chips 5G. Audífonos inteligentes analizan la geometría auditiva. Robots humanoides bailan moonwalk. Nokia y NVIDIA sientan las bases para 6G. De forma simultánea, la geopolítica y la desinformación revelan que una IA sin restricciones éticas se convierte en arma de control masivo. El desafío de 2026 no es tecnológico, sino humano: elegir entre la conveniencia monitoreada y la privacidad consciente. Las alianzas hacia 6G establecerán quién controla la infraestructura digital del planeta. La censura en redes sociales demuestra que la verdad es tan escasa como la paz. Y herramientas como CoPaw ofrecen una alternativa: control total de tus datos sin depender de corporaciones dispuestas a negociar su ética a cambio de contratos militares. Escucha el episodio completo en One Digital y únete a la conversación con los hashtags #PodcastONE, #OneDigital y #MWC2026. El cargo Podcast ONE: 6 de marzo de 2026 apareció primero en OneDigital.

Every other week I'm republishing one of my most popular or impactful episodes and adding an update, new insight, or context that will help you benefit from it even more. This week I'm highlighting Episode 46, where I break down the concept of V/Q mismatch. ____________________Full Transcript- Read the article "What's a V/Q Mismatch?"and view references FREE CLASS - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! Med Surg Solution - Are you looking for a more effective way to learn Med Surg? Enroll in Med Surg Solution and get lessons on 57 key topics and out-of-this-world study guides.  Straight A Nursing App - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store. 

Who dares to make predictions in the current landscape? We do!  Our Predictions are back. Will our track-record continue on a high or will we be fundamentally wrong? Listen in to our Predictions for 2026 Navigation: Intro What will 2026 be all about? AI, AI and … more AI The big Hardware movements Of Start-ups and VCs Regulatory & Geopolitical Headwinds… and the Wars Fintech, Crypto and Frontier Tech Conclusion Our co-hosts: Bertrand Schmitt, Entrepreneur in Residence at Red River West, co-founder of App Annie / Data.ai, business angel, advisor to startups and VC funds, @bschmitt Nuno Goncalves Pedro, Investor, Managing Partner, Founder at Chamaeleon, @ngpedro Our show:   Tech DECIPHERED brings you the Entrepreneur and Investor views on Big Tech, VC and Start-up news, opinion pieces and research. We decipher their meaning, and add inside knowledge and context. Being nerds, we also discuss the latest gadgets and pop culture news Subscribe To Our Podcast Bertrand Schmitt Introduction Welcome to Tech Deciphered Episode 74. That would be an episode about some predictions about 2026. What will be 2026 all about? I guess this year is probably starting with a bang. We saw the acquisition of xAI by SpaceX. We saw an acquisition from Grok by NVIDIA. What’s your take about what would be the big themes in 2026? I guess it would be for sure about AI and space. Nuno Goncalves Pedro What will 2026 be all about? Yeah. I predict a year that will be a little bit more of a year of reckoning in some way. There will be a lot of things that I think we’ll start seeing through. The fact that we are in the midst of an amazing transformational era for technology, the use of AI, but at the same time, obviously, a ridiculous bubble that is going alongside it as we’ve discussed in previous episodes. I think that we’ll start seeing some early reckonings of that, companies that might start failing, floundering, maybe a couple of frauds along the way, etc. I’ll tell you what I will not make many predictions about today, which is geopolitics. Geopolitics, I will not make predictions at all. Who the hell knows what’s going to happen to the world this year in 2026? I don’t dare making any predictions on that. Back to things where I would make predictions. I think on AI, we’ll have a little bit of reckoning. We’ll talk about it a little bit more in detail during this episode. Interesting elements around the hardware and physical space. Physical space, we just dedicated a full episode to it. We won’t go into a lot of details on that, but definitely on the hardware side, we’ll talk a little bit more about it. The VC landscape is going through an incredible transformation. We’ll talk about it today as well and some of our predictions for this year. What will happen to the asset class? It seems to be transforming itself dramatically. Obviously, that has a very direct impact on startups, so we’ll talk about that as well. And then to close a little bit the chapter on this, we will address some regulatory and geopolitical, let’s call it, headwinds without making maybe too many complex predictions. We shall see. Maybe by that time of the episode, we will be making some predictions. You guys should stay and listen to us, and maybe we will actually make some predictions about the geopolitical transformations that we will see this year in the world. Then last but not the least, we’ll talk about fintech, crypto, frontier tech, and a couple of other areas before concluding the episode. A classic predictions’ episode. We normally have a pretty good track record on some of these, but right now, the world is going a bit interesting, not to say insane. Bertrand Schmitt Yes, and going back to some news, Groq technically was not acquired, but, practically, it’s as if it got acquired. I’m talking about Groq, G-R-O-Q. The AI semiconductor company focused on inference AI, and it was late December. It was a way to end the year. This year, we started again with an acquisition of xAI by its sister company, SpaceX. I guess that’s where we are starting. AI, AI and … more AI We are going to start on AI. That’s definitely the big stuff. Everything these days, I guess, is about AI or has to have some connection with AI, or it doesn’t matter. I think every company in the world has seen that. You have to have the absolute minimum on AI strategy. You better execute on this strategy and show results, I would say. For the companies that were not AI native, you truly have to have a way to transform yourself. I guess at some point, the stretch might be too much, and it’s not really reasonable. Then you maybe better stay on what you are doing, especially if you’re in tech, you better be moving faster to AI. Nuno Goncalves Pedro Just to highlight, and I think throughout the episode, you’ll see that there’re obviously a lot of implications that would manifest themselves into capital markets. I mean, we’ll specifically talk about VCs and startups later on. But the fact that everything needs to be AI, the fact that there’s so much innovation happening right now, in my opinion, and this is maybe the first pre-topic to AI, is we’ll see a tremendous increase in M&A activity this year across the board. I mean, we’ve seen already some big acquihires we mentioned in some of our previous episodes, but we’ll see a lot more activity on M&A this year. Normally, that’s a precursor to the opening of capital markets. I predict also that there will be a reopening of the IPO market that never really reopened last year, to be honest. M&A, a lot more, reopening of the IPO market. Normally, it happens in the second or third quarter of the year. That’s what my M&A friends tell me. First quarter of year, everyone’s figuring out stuff. Then last quarter of the year, things should be more or less closed. Maybe the third quarter is the big quarter. We shall see. But definitely, as a precursor to our conversation today, I think we’ll see a lot of M&A, and we’ll see reopening of the IPO mark. Bertrand Schmitt I guess last year was not as big as you could expect on M&A given the tariff situation announced in April and May. I mean, it became quite tough to do IPO in such market conditions. Definitely, we can hope for something dramatically different in 2026. I guess talking about public markets and IPO, I guess the big one everyone is waiting for is SpaceX. SpaceX getting even more interesting with its xAI acquisition. Nuno Goncalves Pedro Do you think that because of the acquisition, it’s more likely that it will happen this year, or because of the acquisition, it’s less likely that it will happen this year? Bertrand Schmitt That’s a good question. My guess is the acquisition of xAI is all about xAI needing more financing and cheaper financing. This acquisition is a pathway to that. SpaceX being a much bigger company, a company that is also making much more revenues. I could bet that there is higher probability that, actually, SpaceX will go public in order to finance itself. At the same time, will it have enough time to prepare itself for the IPO given this acquisition just happened? Can they do that in 6 months? I mean, if anyone can do it, I guess it’s Elon Musk. It’s a strategy to present an even more attractive company with an even more interesting story, a story of vertical integration from AI to space. I guess the story as it’s presented itself right now, it’s one about having your AI data centers in space. Because in space, you have much better solar energy production with solar panels. You have a perfect cooling situation because you are in space. Thanks to Starlink, you have the mean to communicate between the satellites and with Earth itself. I think if someone can pull up a story like AI data center in space, I guess Elon Musk can. There is, of course, a lot of questions about is it practical? Is it economical? Yes. I certainly agree. I’m not clear on the mass, and can you make it work? Again, I mean, Elon Musk single-handedly, with SpaceX, managed to transform the space market on its head. I mean, they are the biggest satellite launching company in the world. They have the most satellites in the world. I mean, I’m not sure I would bet against him, and I guess I would probably believe that he could pull up something. Time frames, different story. The 2-3 years data center in space for AI as cheap as on Earth, I have more trouble with that one. I mean, it’s a usual suspect with Elon Musk. You promise something unachievable in a few years, but, ultimately, you still manage to reach it in 5 or 10. Again, I would not bet against the strategy. Nuno Goncalves Pedro Yeah. I’ve talked to a couple of space experts, people that have launched rockets, and have worked JPL, NASA, and a couple of other places, etc. For what it’s worth, their feedback is, “No way in hell, and we’re decades away.” We’ll see. I mean, to your point, Elon has pulled very dramatic stuff. Not as fast as he normally says he’s going to pull it, but within a time span that we all see it. Difficult to bet against him. In terms of actually the prediction, maybe to respond to the prediction as well, will SpaceX IPO? I’m going to make a prediction that has a very high likelihood of missing the mark, but I think Tesla’s going to buy and merge them both into it. It’s going to become a public company through Tesla. That’s my hypothesis. Bertrand Schmitt No. That’s supposed to be it. That’s how you solve that. Nuno Goncalves Pedro And Elon controls the whole universe. X, xAI, Tesla, SpaceX, all under one umbrella beautifully run. And SolarCity is well in there, of course, so wonderful. Bertrand Schmitt That’s possible. Certainly, you are not the only one thinking Tesla will acquire or merge with SpaceX. To remind everyone, Tesla is around 1.3, 1.5 trillion market cap. Depending on the day, SpaceX seems to be valued at similar range, 1.2, 1.3 trillion. It looks like it’s the most valued private company at this stage. These are companies of similar size, so that’s one piece of the puzzle. When you think about the combined company, we could be talking about a 3 trillion entity. Playing right here with the biggest companies in the marketplace today. Nuno Goncalves Pedro With a couple of tweets from Elon, it will rapidly get to 4 to 5 trillion. Bertrand Schmitt That’s so tricky. Nuno Goncalves Pedro Yes. On AI and back to AI, one thing I think that we’re about to see is this will probably be the year of agentic AI. Obviously, we predict a lot of growth on that side of the fence, in particular on the enterprise B2B side. We see a lot of opportunities coming through. From our perspective, at least at Chamaeleon, we generally believe that there’s going to be a lot of movements on agentic AI. It’s also going to be probably the year of the first big fails of agentic AI that will be newsworthy. There will be some elements about that loop and how it gets closed that will happen. I think we might see some scandals already. We’re already seeing the social network of bots talking to bots. We will see other scandals going on this year even in the consumer space and in the bot to bot space, which we now can talk about or in the AI agent to AI agent space. My prediction is we will see some move forwards. There’ll be some dramatic funding rounds along the way. We’ll see a couple of really cool things out of the gates coming out that are really impressive, but we’ll also see the first big misses of the technology stack. I don’t think we’ll go fully mainstream yet this year, so it’s probably maybe something more for 2027 along the way. That would be my prediction again. I think enterprise will lead the way. We’ll definitely see a lot of stuff on consumer as well that is cool. Then we’ll all have our own personal assistance in our hands, basically, literally in our phones. Bertrand Schmitt Going back to agentic AI, we also started the year with some pretty dramatic move. I mean, the launch of Clawdbot, renamed OpenClaw. I mean, this stuff took fire in like a week or 2. It was coded by just one person who actually didn’t even code the product but used AI to build the product, 100% used AI, proposing some new ways also to leverage AI to do coding. He has a pretty unique approach. It’s not vibe coding. I would say it’s a better way to do that. Then the surprising evolution with the launch of a social network for AI agents, Moltbook. I mean, this stuff, probably there is some fake in it. But at the same time, I think it’s quite impressive because it’s the first time we see truly 100,000 plus agents communicating directly to each other. Yeah. I mean, that’s the first time we see surfacing the possibility of some sort of hive mind on the Internet. It’s pretty surprising. Right now, all of this is a hack done in a few days. By end of year, by 2 years, 3 years, we might discover that, actually, the best approach to AI might not be the AI assistant like we are doing today, but a combination of hundreds of thousands of AI working closely together. We might be witnessing the first sign of new intelligence in a way. Nuno Goncalves Pedro Things like this social network might either be Skynet, the beginning of Skynet. They might be the beginning of Her, or they might just be a fad and nothing really happens. It’s just interesting to see what these agents are doing. Bertrand Schmitt Totally. Nuno Goncalves Pedro Obviously, there are real and clear and present dangers of some of the integrations of AI we’re seeing in the market. Interesting enough, and I’ll ask you for your prediction a bit, Bertrand. I think we’ll probably see the first big mishap of AI being used in some infrastructural decision in the age of AI. I mean, we’ve seen AI issues in the past and software issues in the past. We talked in previous episodes about that as well. Mishaps of software that have led to people dying. But I think probably the first big mishap will happen this year as well. Very public mishap of the use of AI and serve its interactions with infrastructure or something that’s very platform related, etc, that will have big impact that everyone will notice. That’s my prediction for the year as well. We’ll have the first big oops moment, as I would call it, for AI in this new age of full on AI. Bertrand Schmitt I would say first some perspective. I think today, people are not using AI directly for life and death decision, at least not that I’m aware. We’re not going to let AI fly a plane, for instance, tomorrow so you can be, reassured. At the same time, given there is such a race to AI, there definitely might be some mistakes. We were talking about the social network for AI agents, Moltbook. Apparently, all the keys used to secure the AI were shared by mistake because it was not properly locked down. We can see that indirectly, mistakes will be made for sure. Two, it’s highly probable that some people will trust AI too much to do some stuff, and this stuff might not work and might have some grave consequence. Hopefully, there is not so much of this. Hopefully, it’s mostly AI used for the good. But you’re right. I mean, at some point, the more we use the technology, the more there would be issue. I mean, it’s highly probable. Nuno Goncalves Pedro That will lead me to another prediction, which is, and we’ll talk about more of it later, but it probably will lead to the first significant movement in terms of regulatory environment certainly in the US at some point if it happens in the US in particular, where there will be some movement that will be like, “Hey, you guys can’t do this anymore.” Because this will probably emerge from mismanaged interfaces. From systems having access to stuff that they shouldn’t have access to in the first place. Talking a little bit more about what’s happening in AI. You’ve already mentioned some of the issues that relate actually to security and cybersecurity. We keep talking about AI. We keep talking about all these infrastructure pieces and platforms that are being built. I think we’ll have a lot more incidents like the one you just mentioned where things will be shared that shouldn’t have been shared, where people will break systems and get into it, etc. Let’s see where that takes us, which is a little bit ironic because, obviously, with AI, the promise is that cybersecurity becomes more robust as well because there’re agents working on our behalf on the cybersecurity side. There’s also agents working on the other side. Bertrand Schmitt It’s a constant race. It’s the attackers, defenders. Each time you have new technology, you have a new race to who is going to attack or defend the best. Each new wave of technology, it’s an opportunity to challenge the status quo. Nuno Goncalves Pedro The attackers have been winning, and I feel they’ll continue winning in 2026. I think it’s going to still be a year of attack. We’ll see more and more breaches, more and more stuff that will happen. Bertrand Schmitt I don’t know if they will win. I mean, it’s normal that they win once in a while. For sure, some infrastructure is not updated as it should. Some stuff are not managed as it should, so there will always be breaches. I don’t know if things are dramatically going to change because, again, everyone who cares who is going to update his infrastructure with AI for defense. There is no question that you have no choice. We will see. That I don’t know. For sure, AI will be used to attack directly with AI. Maybe you’re able to do bigger, larger scale attack. Or thanks to AI, you are simply able to create new type of attacks more easily. AI can be used behind the scene as a way to prepare and organise new type of attacks, even if it’s not used directly live in the battle. Nuno Goncalves Pedro One topic that we’ll come back to later is the geopolitics of everything, but maybe more broadly. On the geopolitics of AI, it’s very clear that we have an arms race going on. Obviously, the US on the one hand, China on the other hand is the two extremes, putting tremendous amount of capital into data centers just at the base of that infrastructure. Chipset development, chipset access, a huge theme in terms of the export restrictions, etc, that are being forced by the US. I think it will continue. From a European standpoint, obviously, they’re stuck between a rock and a hard place, to be very honest. Let’s see what happens on that side of the fence. My view of the world is that certainly from a US and China perspective, we’re going to see a lot more movements in 2026, like big movements. The Chinese movements we always see in delay.  It takes us a couple of months, sometimes even more than that to understand exactly what’s going on. I think we’re going to see some huge moves this year in terms of the States, the United States of America, and China really pouring capital into the creation of the next big winners around AI. I think the US is obviously more visible. We see a lot of these companies. We’ve just discussed xAI and its acquisition by SpaceX or merger. I don’t know what they’re calling it exactly. Effectively, on the China side, the movements I think are already very big. As I said, it will take a while to figure out exactly what those moves are. One thing that I propose is that at some point, China will have very little dependency on chipsets from the US. I’m not sure it’s going to happen this year, but I think the writing is on the wall. Irrespective of any other geopolitical issues that is coming to the fore at this moment in time. That’s one of the key areas or in arenas of fight. Bertrand Schmitt It makes sense. If you are China, you will look at what happened. You would think that you cannot just depend on the largest of one country. It makes rational sense, the same way it makes rational sense for the US to limit exports to China because there is value to delay some peer pressure that could use these technologies for good but also for bad. If you were an ally of the US, that would be one thing. But when you are not an ally of the US, that certainly should be a different perspective. Maybe one last point concerning agents, I think there will be a lot that will revolve around coding. We can see OpenAI with Codex. We can see Cloud with code. There was, of course, [inaudible 00:18:28] that was trying to be big on agentic coding. I think agentic coding was one of the big transformation in 2025 and is going to get bigger in 2026. I think for a lot of people who do coding, there was a radical transformation in terms of what you can achieve, what you can do, how much you can trust AI to help you code. I start to think we might see this year, the replacement of not just one AI replace one coder, but one AI replace a full team because of the new ability to manage that at scale. Coding might be a common activity where you are going to think about outcomes, think about objective, think about how you organise, but not really coding by itself anymore. A big change, like you used to code, directly your hand on the stuff, but step by step, everyone is going to become a manager of agent. I think in one year, we saw enough transformation to think that in the coming year, the transformation can be even more dramatic. Nuno Goncalves Pedro The big Hardware movements Now switching gears to hardware. Obviously, a lot of movements in 2025 and over the last few years. One piece of thesis that we’ve had long-standing at Chamaeleon is that we will see the emergence of AI devices. Some of them have been tremendous failures as we discussed in the past. I predict that we’ll have a couple of really interesting full stack AI devices in the market this year. Why does that matter? Because, as many of you know, obviously, there’s compute that can happen in data centers and cloud infrastructure all over the world, but also there’s compute that can happen at the edges. The more you can move to the edges and the more you can create devices that actually allow you to have user experiences that are very distinctive at the edge, the more powerful some of these devices might become. I predict Apple will not be the first to launch anything on this. I predict probably OpenAI, after the acquisition of IO, will maybe not launch something this year, but will announce something this year. I’ll step back on that prediction. They’ll announce something this year, but maybe not launch. But we’ll start seeing some devices that have some interesting value in the market, probably devices that are AI devices, but they are very focused on very specific user flows, and so very much adequate to specific activities. I won’t make a prediction on that, but I think areas that would make sense for that to happen would be obviously around fitness, health, et cetera, et cetera, where we already have the ascendancy of products like Oura Ring and others out there. Definitely, that’s one area that might have quite a lot of developments. I think AI-first devices, devices that are very focused on compute at the edges, providing user flows that are AI-enabled to end users, we’ll see a lot more of that and a lot more activity this year. Again, I don’t think Apple will be necessarily ahead of the game. Again, maybe OpenAI will give us something to at least think about and look forward to. Bertrand Schmitt First, I’m not sure it will be that transformational because if it’s not in your phone, in your pocket, there is only so much you can do with it, and there is only so much computing power you will have. I’m doubtful it would be really impactful this year. Nuno Goncalves Pedro I feel we’ve been discussing this shift of paradigm in input and output. For me, some of these devices could lead to that shift. Because, again, a mobile phone is not a great long-term paradigm for the usage that we have because it’s really constrained by the screen. The screen is really what takes most of the battery life away. If we didn’t have that screen, what could we do? If we have the block that is as big as a mobile phone, and it didn’t have a screen, it was just compute, that’s a mini computer, a microcomputer. Bertrand Schmitt That’s a fair point, but I don’t see that transformation this year. That’s really more my point. I can see that you can have AI-enabled smart glasses, and it’s clear there is a race to AI-enabled smart glasses. My point is more to go beyond the gadget, it would take quite a while. It would need to have cameras. It would need to analyse what you see. It would need to hear what you hear. Again, it might come, but then at some point, it would be okay, what do you do with it? We have the example of the movie Her. That’s showing Her what it could be. There are definitely possibilities. It’s clear that if you take the big VR headset like the Apple Vision Pro, there is a failure from that perspective in the sense that I think it’s a great, amazing device. The big problem is that it’s doing way more that makes sense. I think there will be a clearer separation between your smart AR glasses that has to be light, that has to be always unconnected, and that’s primarily there to help you make sense of the world around you. The true VR headset that doesn’t really require much in terms of AI, and it’s just there to immerse you in a different world. For this, we know, unfortunately, in some ways, that there is not a lot of demand for it. Maybe there is little demand because you are too hidden in your own world. The technology is not working well enough yet. There are a lot of reasons. But I think Apple trying to do both at the same time, AR and VR, with the Vision Pro, was a pretty grave structural mistake. I think we would see a clearer line of separation between the two. There is bigger market opportunity for AR glasses. That, I certainly agree. There is opportunity to connect that to a computing device. As you talk about, your glasses are your screen, your phone becomes something in your pocket connected to your glasses. Nuno Goncalves Pedro For me, Apple has their way of doing things. From the perspective of what you said, they normally really plan their devices. Even if it’s a big shift in terms of a new area, like they tried with the Vision Pro, and we criticised them for launching it as a device that should have been more of a dev device that they really launched as a full-on device, but that’s their playbook, classically. I think Apple needs to change how they put products out and how they experiment with those products, et cetera. I think they have enough money to be doing everything all the time and figuring it out. If they don’t want to put it out, then they need to do a lot more hell of testing internally with their silos, but they should be playing across all these arenas, VR, AR, everything. They just should put devices out that are either ready for prime time, or they should call it something else. They should call it like this is a dev device or whatever it is. Bertrand Schmitt I agree with you. My complaint is more that it was marketed as a consumer device when it was not. It was a true developer device. Two, they tried to mix the two at once, and it made no sense. No one is going to walk in their home or in the street with their Vision Pro on their head. You have to be deranged, quite frankly, to have use cases like this. I think that for me is a crazy mistake from a company like Apple that prides itself in pure UI, pure user interface, very well-designed device for one specific use case, not mixing the two use cases. We still don’t have Macs with a touchscreen, you know?  We still don’t have an iPad with a good OS that makes use of this great hardware. For some strange reason, they decided to mix everything in the Vision Pro with a device that weighs a ton on your head and is so uncomfortable. That’s why, for me, I’m like, “Guys, what is wrong? Why did you let this team run crazy?” I hope at some point, Apple will go back to the drawing board. My understanding is that that’s what they are doing. They are going to have two devices, one smart glasses, an evolution of the Vision Pro, just focus on VR. They might actually abandon the concept of the pure VR-oriented headset. Because, from a market size perspective, it might not be big enough for Apple, quite frankly. Nuno Goncalves Pedro I read on all of the above, and people at this point was like, “Why are then players like Samsung and others not doing it. LG, et cetera?” Because those players historically have not invented new categories. They’re amazing at catching up once the category is invented, and then they scale the hell out of it, and that’s what these companies have been exceptional at. I wouldn’t see a dramatic innovation, I think, in terms of devices coming from any of the big ones on that side of the fence. Not to disrespect them in any way, but I think that’s not been their playbook ever. Again, if the origination doesn’t come from a start-up or from an Apple, I don’t see those guys going after it. My bet is that we’ll see some start-up activity and, again, hopefully, some announcement from IO now within the OpenAI world. Bertrand Schmitt I would slightly disagree with you. I see where you are coming from. But take the Samsung Galaxy Note, that sudden much bigger headphone that no one was doing that was launched by Samsung, at some point, it forced Apple to launch an iPhone Max. Let’s look at the Z Fold that Samsung launched 7 years ago, copied by everyone. Now Samsung launching a trifold. Apple has still not launched their foldable phone. I think there is a mix, actually, of sometimes- Nuno Goncalves Pedro For me, that’s not a proper new category. It’s still a mobile phone. It just happens to have a screen that folds in half. Bertrand Schmitt The iPhone was still a mobile phone, you could argue.  Nuno Goncalves Pedro No. I think the iPhone was…  I could actually agree with you on that point. Maybe Apple is not as innovative in that case. I think what Steve Jobs was exceptionally good at in terms of his ability as this master product manager was to be an exceptional curator of user flows and user experiences, and creating incredible experiences from devices based on that. That was his secret sauce. Could you say, “Wasn’t all of this stuff already around?” It was. You just put it all together very neatly and very nicely. But if you’re talking about significant shifts in how a category is done, the iPhone was a significant shift in how the category was done. The Fold is still an interesting device. I actually have a Fold right now in front of me. The 7 that you highly recommended to me that we both got, the Z Fold 7. I think they do amazing devices. I don’t think they normally are the most innovative players. Then, when they come to innovation, it comes from technology edges. Obviously, they have Samsung Display, there’s a bunch of other things. They had the ability to do foldable screens in-house themselves. Bertrand Schmitt I don’t disagree with you. I think there is an interesting situation where some companies have some strengths, another one has some strengths. My worry with Apple is that this was not demonstrated with the Vision Pro. The Vision Pro was a hot pot of technologies barely integrated together, with use cases absolutely not well-defined and certainly not something that makes sense for most of us. There is a question of has Apple lost it? While Samsung actually keeps doing their own stuff, that, yes, might be more minor improvements, but at least they are doing it. Because it looks like Apple is missing the train on even the minor improvements. By the way, you might not be aware, but Samsung launched its Vision Pro competitor. Interestingly enough, it might be a better product in some ways, being much lighter and much more comfortable. Nuno Goncalves Pedro We should play around with that and report back to our listeners. Of Start-ups and VCs Moving to venture capital and the startup ecosystem and what’s happening there, I think it is very much a bifurcated environment, and it’s bifurcated for both VCs and for startups. If you’re a startup in the AI space, and you have the hottest team since sliced bread, and you can create FOMO at the speed of light, you can raise ridiculous rounds. Five hundred million at the $3 billion, or $4 billion, or $5 billion valuation, and you still haven’t really even started. First round, you can raise 500 million. That’s back to the whole discussion on Bubble and where are we, et cetera. Some of these companies might actually become huge, some of them might not. But definitely, we are seeing really the haves and have-nots on the startup ecosystem with incredible teams raising a lot of money very, very early on or mid-stage if they’ve already existed for a while, and then the rest not being able to raise. We see a lot of non-necessarily AI sectors, some of the areas of SaaS that don’t necessarily have AI in it, or fintech, or the consumer space that are really, really struggling. If you don’t have an AI story for your startup right now, it’s extremely difficult to raise money unless your numbers are just the best numbers ever. That’s, I think, the first part of the element of bifurcation that we’re seeing today. The second element of bifurcation that we’re seeing today in terms of fundraising is for VCs themselves, and really propelled by the large VC firms raising more and more capital in recent orbits, announcing 15 billion across funds raised. Lightspeed, I think, had made an announcement a couple of weeks ago as well. They’ve raised a bunch of money as well. The big guys are all raising a lot of money. At some point in time, the question some of you might ask is, “These VCs are redeploying more and more money if they have a couple of billion for a VC fund. How does that look like? Is that still VC?” My perspective, I’ve shared before in some of our previous episodes, is that that’s no longer venture capital. At that point in time, we’re talking about something else. Private equity hedge funds, if you want to call them, maybe funds that are really driven by growth investment or late-stage investment. If you have a couple of billion under management, you’re not going to make your returns by writing a $3 million check in a series seed and leading that round.  That has implications for everyone in the ecosystem. It has implications for smaller funds that obviously have a lot more difficulty in raising capital. It’s difficult to differentiate. Last but not least, also for startups that really continue searching for that capital that is out there. Andreessen Horowitz, for example, runs Speedrun, which is a great program for companies around consumer in particular. Initially, it was a lot for gaming. But at some point in time, Andreessen Horowitz could decide that they don’t want to invest more in you. They just put money from Speedrun, which is obviously a very small check compared to the very large checks they could write mid to late stage and that will have an effect on you as a startup. What happens at that point in time if Andreessen Horowitz is not backing you up in later stages? More than that, what happens if I can’t get these big funds interested in me? Are the small funds still valuable to me? Punchline, my view is yes. Obviously, we’re a smaller fund, so there’s parochial interest in what I’m saying. Small funds can still create a ton of value for you, also in terms of credibility, ability to accompany you in those first stages of investment, and the ability to bring other larger investors later down the road as well. There’s definitely a big movement happening in terms of the fundraising for VC funds, which we shouldn’t neglect, which is the big guys are raising a lot more capital and are therefore emptying the market to smaller funds that are having more and more difficult raising at this point in time. We had discussed that there would be a need for concentration in the industry, that micro funds would need to concentrate, and we didn’t have the space for so many micro funds as we had around. But the way it’s happening is extremely dramatic at this moment in time. I think it will continue through 2026. Bertrand Schmitt Remember a few years ago, with the rise of AI, there was more and more of the question about, “What’s the point of SaaS at this stage?” Because SaaS was around for 15 years. Basically, how do you come up with something new that was not already tested, validated by the market? How do you bring something new? We say this was reinforced to the power of 10. If your product is not clearly built from the ground up for a new use case enabled by AI, anyone could then might have built your product 5, 10 years ago, and therefore, why now has no clear answer, and it’s a big problem. I’m still surprised myself to still see some entrepreneurs where you talk to them about AI because you don’t see them in the deck, and they explain to you, “It’s not yet there,” and you’re like, “What’s wrong with you guys?” Fine. Do whatever you want. Do a small business and whatever, but don’t think you can come up pitch and raise without an AI story. The second category is people who come with an AI story, but you can feel very quickly, I guess you saw that many times, Nuno, where just a story layered on top with little credibility. It’s not better. It’s not enough to just have a story. Your business needs to be radically built differently or radically proposing some brand-new use cases that were impossible to solve 5 years ago. Nuno Goncalves Pedro To stack up on that, absolutely in agreement. If you’re just adding to the story, and it’s an afterthought, and you’re just trying to make the story somehow gel, once you go into one or two layers of due diligence, your investors will very quickly realise that you’re not really AI-first or dramatically AI-enabled or whatever. It’s just you’re sort of stacking something on top of another thesis. It needs to make sense from the product onwards. It’s not just, let’s just put it together with chewing gum, and magically, people will give you money. It was true also if we remember the good old crypto blockchain days, where everyone’s investing in crypto. A lot of stories that didn’t make much sense. In that sense, it’s not very different. I would go one step further. I think in the world of the VC winter that we’re a little bit in, where it’s more and more difficult if you’re a smaller fund to raise your fund at this moment in time, there’s a lot of sources of distinctiveness still talked about, like proprietary networks, access to deal flow, fast track record, all that stuff that really, really matters. But our bet continues at Chamaeleon continues being that you need to be AI-first as a VC fund yourself. You need to have core advantages in using not only readily-available AI tools or third-party available AI tools, data sources, technology stacks, but actually building your own stack over time, which is what we did with Mantis at Chamaeleon. Again, just to reinforce that, I think we’re at the beginning of that stage. We, Chamaeleon, are ahead of the game, but we think that the rest of the market will have to move towards that as well. Still, to be honest, very surprising to me to see that many significant large players are doing very little still around some of these spaces. They have data scientists. They’re running some tools. They’re running some analysis and all that stuff, but it’s still, again, back to the point I was making for startups, all glued up with chewing gum. It doesn’t all come together nicely, which it does need to from a platform standpoint. Bertrand Schmitt It’s quite surprising. I agree with you that some VC funds might think that they can do business as usual in that brand-new world. It’s difficult to believe. Nuno Goncalves Pedro Maybe moving a little bit toward the capital formation piece. We already discussed the M&A space really accelerating. We’ve also discussed the IPO market and some predictions on that. Secondaries, there’s obviously a lot of liquidity coming from secondaries from mid to late stage. I think it will continue throughout the rest of 2026. A lot of activity in buying, selling in secondaries as some asset managers are becoming more distressed, as some very high net worth individuals and family offices are becoming more distressed as well, at the same time, where there’s a lot of opportunities to potentially arbitrage around some investments. I believe a lot of money will be made and lost this year by decisions made this year, just to be very, very clear in terms of equity, purchases, et cetera. Exciting year ahead of us. Definitely a very, very interesting market ahead of us. Secondaries, M&A, growth, and late-stage investing, also, early-stage investing will continue just for those that were wondering. Last but not least, the public markets, the IPO market as well. Bertrand Schmitt One of the big questions for the IPO market would be, will SpaceX go public? Would it be good for the startup ecosystem? Because suddenly that they go public, it would be to raise money. If they raise money, will there be any money left for anybody else? That would be an interesting test of the market. For sure, it would be proof that market are risk on financing a new IPO like this one. Or as you said, maybe there is no IPO, and it’s a merger with Tesla. Time will tell. Nuno Goncalves Pedro Regulatory & Geopolitical Headwinds… and the Wars Moving maybe to our topic of regulation and geopolitical headwinds, as we’re seeing … definitely not tailwinds. The Google antitrust verdict and, obviously, the remedies are expected to come forward now, and a lot of people are saying, “There are some risks of structural separation.” What do you think? Is it cool, but nothing will happen in the end dramatically? Alphabet or Google? I’m not sure, actually. It’s Google LLC. I think that’s the case. It’s The United States versus Google LLC. Bertrand Schmitt I’m not sure. Personally, I’m not a big fan. I think there needs to be a better way to manage some anticompetitive behavior. I’m not a big fan. There was this temptation to do that for Microsoft 25 years ago. Look at what happened. No one needed to buy Microsoft to leave space for others. I see the same with Google, and I guess they are happy to not be the number 1 in AI today, but to have an open AI in front of them. Even if they are doing a great job, by the way, to move forward and go faster and faster. Personally, quite impressed now with some of what they have released. Gemini 3 is doing great from my perspective. I’m not a big fan of this. I think to be clear, it’s important that bigger companies don’t behave anticompetitively, but at the same time, we need to find the right approach where it’s not about breaking these companies, and it’s also not about forbidding them to do acquisitions. Because then you end up with what NVIDIA just did with a $20 billion acquihire IP licensing type of acquisition, because they didn’t want to have the uncertainties. They didn’t want to wait 1–2 years in order to acquire the people and the technology, so they organised it in a different way. But I don’t like that. I think they should be able to acquire companies without facing so much uncertainty. To be clear, it’s not new. Uncertainty when you are Google, NVIDIA, or others, it happens. It has happened for a decade plus, 2 decades. I think there needs to be, for sure, some safety valves. At the same time, we want an efficient capital market. An efficient capital market need companies that can acquire other companies. If you don’t do that efficiently, it will be worse for the entrepreneurs, it will be worse for the investors, it will be worse for everybody. I think we have not reached a good equilibrium from my perspective. We need more efficient acquisition process. And at the same time, we need to also enforce faster anticompetitive behavior. Because what you talk about concerning Google, this is a case that was what? That is 10 years old. You see what I mean? This is way too long. If you’re a startup, you are dead by then. It’s like the story of Netscape facing Microsoft. They were dead long after the fact. I think we need a different approach. I’m not sure the best answer. I’m not sure we’ll get a better approach. There are probably too many vested interest. My hope is that it will get better with this current administration because, certainly, the past administration was very anti acquisition and efficient markets. Nuno Goncalves Pedro We’ve talked about the European Union AI Act a bunch of times, so I don’t want to spend too many cycles on that. The only effect that I would say is we are seeing in very slow motion the splitting of the Internet. I once had Tim Berners-Lee, by the way, shouting at me that we were going to break the Internet when we were applying for the .mobi top-level domain. I was part of that consortium that eventually did get the .mobi top-level domain, and I had him shouting at us. But, apparently, this is going to split the Internet, Tim. So in case you’re listening. Because it will create all these different rules. If your data is relating to consumers there, then it’s treated in a different way, and The US is… Well, obviously, we have the case of California with its own rules and laws. I don’t know. I feel we’re having a moment of siloing that goes beyond economic and geopolitical siloing. It will also apply to the digital world, and we’ll start having different landscapes around it. We’ll see how this affects global expansion of services, for example, around AI, particularly for consumer, but I don’t foresee anything dramatically positive. Recently, we had the whole deal around TikTok finally having a solution for their US problem where there’s now a US conglomerate magically that owns it. The conglomerate doesn’t magically own it, they just straight up own it for the US. But it was driven by many of these concerns around data ownership. Where’s the data? Where is it based? I think a lot of other concerns that have to do with the geopolitics of China, obviously, being the basis of ByteDance, the owner of TikTok, that still is a significant owner, by the way, in TikTok in US. Then also the interest in the economics of making money out of something as powerful as TikTok, to be honest, in The US. Just to be clear, I don’t think this was all about the best interests of consumers. It was also about money. Just follow the money. Bertrand Schmitt There are for sure, some powerful interest at play. But let’s be clear. I think one is data, as you rightfully said, but the other one is algorithm. It’s not as if China is authorising any competitor on its territory. They have blocked access to most of the Internet platforms from the US, either finding new rules or just trade blocking them. So I don’t think it’s fair competition. You don’t want some of that data in China about the US or European consumer. Three, it’s about the algorithm. If suddenly, you are a foreign power, and you can as we know in China, you better follow what’s required of you from the Chinese Communist Party. You cannot take a chance with influencing other stuff like elections in other countries. It’s fair from the US perspective. One could even argue it’s fair from a Chinese perspective to want that. I think the only one in the middle who doesn’t really know what they want is Europe because on one side, they want to benefit from American platforms, on the other end, they want to have some controls. On the other end, they don’t create the environment for startups to flourish. So in that weird situation where they have to accept some control by the big US providers and either provider of underlying infrastructure or provider of consumer business facing services. Then they try to regulate them. But I think they are misunderstanding the power relationship, and I think some of this regulation would get some blowback, at least by the current administration. Just, I believe, this morning, there was some news around X being under a criminal investigation in France. This is not going to end well for the French startup and VC ecosystem. This is not going to end well for France and Europe when you depend so much from your American friends. Nuno Goncalves Pedro Regulation will be weaponised. Regulation constraints around exports, all of this will be weaponised geopolitically, and the bigger guys will normally win. I think that’s normally what we’ve seen. Just on TikTok just to… And you guys, if you’re listening to us, just see if you see a pattern here, but obviously, 19.9% still owned by ByteDance of the TikTok entity in the US. It was initially said that 80% of the TikTok entity is owned by non-Chinese investors. Initially, people were saying US investors, and then they changed it to non-Chinese because MGX, I think, has 15% of it. MGX is based in the UAE, connected obviously to Mubadala, the Abu Dhabi sovereign wealth fund. Silver Lake is in there, I think, with 15% as well. Oracle as well with 15%. Those three are the big bucket owners together, 45%. Silver Lake having collaborated with MGX before, and I’m sure a lot of connectivity there. Then you still see a pattern in this in terms of shareholders. If you don’t, then just Google it. Dell Family Office, Vastmir Strategic Investments, which is owned by billionaire Jeff Yass, Alpha Wave Partners, obviously involved with a bunch of things like SpaceX and Klarna, Virgoli, Revolution, which is Steve Case’s, a former founder of AOL, is also in there. Meritway, which is managed by partners, I think, of Dragonair. Vinova from General Atlantic, an affiliate of General Atlantic. Also, NJJ Capital, which I believe is Xavier Nil, the French billionaire that founded Iliad. Mostly American, I think, if the math is correct. 80% non-Chinese, which was what mattered, I think, in many cases. But do see if you saw a pattern in most of those investors. I won’t say anything more than that. Maybe moving to other topics, maybe just to finalise on regulation and geopolitics. In geopolitics, we should talk about wars if we predict anything. Not that we are nasty and one want to be negative, but what the hell is going on? Will we have ending to the wars we already have ongoing or not? But before that, the struggles on the App Stores, I think, will continue both for Apple and for Google Play Store. The writing’s on the wall, the EU keeps pushing it dramatically and Apple keeps just doing stuff. I’m on the board of an App Store company. Apple just creates all these things that basically make you not really… It doesn’t work. You can’t provision then an App Store on Apple devices. On iPhones, et cetera. We’ll see how that will continue going, but I feel the writing’s on the wall. Both Apple and Google will have to open up a bit more of their platforms. I’m not sure it will have a huge impact in the medium to long term, but definitely we need to see more openness in access to apps as given by the two big platform owners, Apple and Google, out there. Bertrand Schmitt Let’s be clear. Google is way more open than Apple. We both have Android devices. You can install alternative app stores. It’s a different ballgame by very far. Nuno Goncalves Pedro Google does other nasty stuff. It’s public. You can check which board I’m a part of. You can see what that company has done towards Google over time. But to your point, yes. It is true that Google has been more open than Apple, but Google has done their own things. Just to be very clear, so I’ll just leave that caveat bracketed there for people to think about it and maybe read a little bit about it as well. Bertrand Schmitt I can say that, me, from my perspective, that path of total control that Apple has been going through on all their devices, that includes macOS, pushed me to, over the past 2, 3 years, to completely live and abandon the Apple ecosystem. I just couldn’t accept that level of control, that golden handcuff approach of the Apple ecosystem, each their own obviously, they are golden, their handcuffs, but they are still handcuffs. Personally, that pushed me way more to Linux, Android, Windows, back to Windows after all these years. I just couldn’t stand it anymore. I want to pick my devices. I want to pick what I install on them, and I don’t want to be controlled like this by just one entity for all my tech devices. For me, at some point, it was just not acceptable anymore. It’s still very warm, very golden handcuffs, but for me, they were just handcuffs at this stage. Yes, what they are doing with the App Store is very typical of that mindset. I think it’s quite sad because I think it started with good intention in some ways. “We need a new computing paradigm, we need to make things smoother and safer,” but it has really become a way to control your clients. For me, it has reached a point where it’s just way too much. Nuno Goncalves Pedro There’s obviously the great power comes great responsibility that uncle Ben told Spider-Man or Peter Parker. But there’s also with great power comes shitload of money, and control. So it’s like, “Yeah. Should we open the server? Do we want to delay opening it up?” “Yeah.” Anyway, it is what it is. Maybe let’s end on the more difficult note of the episode, which is going to be around wars. What’s our prediction? Will we have an end to the Gaza situation with Israel? Will we have an end to Ukraine and, obviously, Russia? What will happen in Iran? Those are the three big, big conflicts right now. Then, obviously, if we want to add just bonus points, what’s going to happen to Greenland, and what’s going to happen to Taiwan, and what’s going to happen to Venezuela? Let’s throw the whole basket in there. We’ve never had like… Let’s talk about all these territories and all these countries. At some point in time, I’m saying this in a light manner, but it’s obviously more tragic than it should be light, and people are dying, and there’s a lot of implications of all of that that is happening right now. Do you have any predictions, Bertrand, for this year? Bertrand Schmitt No. It’s tough to predict on an individual basis. I think on a more bigger picture basis is on one side, obviously, the rise of China on one side. You have also the rise of other countries like India, while very indirectly connected to some of these conflicts are still part of the game, buying oil from Russia, for instance. At the same time, I think overall, the US is more clear about with the sheriff in town. I think it’s good because in some ways, you cannot pay for the goods, you cannot have such a massive advantage versus nearly every other country on earth and just not be clear about who is the boss in some ways. As a result, what are the rules of the game and how it should be played? The US is not alone, obviously, you have China, you have Russia, you have India, you have Europe. You have different other countries. But at some point, it’s not good when countries are not rational and are not clear. I think I prefer the current situation where things are more clear and where you have to assume responsibilities about what you are doing. It’s time to be rational again about how the world behave. Yes, the concept of power and balance of power. I think there has been that dream, maybe mostly coming from Europe, about the end of history. I think that’s simply not the case. It’s not the end of history. It’s still about the balance of power. It has always been about the balance of power. If you are dumb enough to think it was not about that anymore, I just have a bridge to nowhere to sell you. I don’t have specific prediction, but I think it’s clear there is a new sheriff in town. There is a new doctrine about the Western Hemisphere that has been in some ways resurrected on the [inaudible 00:51:35] train, and I think we’ll see more of it. I think at this point, the biggest question is for the Europeans. What do they want to do? Because right now, their position of being a dwarf militarily while being a pretty big giant economically, I don’t think it works. Nuno Goncalves Pedro I agreed on everything that you said. I do have predictions. I’ll stick a flag on the ground just with my predictions. Bertrand Schmitt Good luck. Nuno Goncalves Pedro They are mostly positive. I do think we’ll see an end or, for the most, end to the two big conflicts, the one in Gaza and the one in Ukraine. I think Ukraine will end up in readjustment of territory and splitting between Russia and the Ukraine, but the end of hostilities, I think that we will see an end to the conflict in Gaza also with a readjustment on what that will mean for the Palestinian territories and the Palestinians in general. That I’m not sure, but I feel that there will be an end to those two big conflicts. Iran, I have no clue. I will not put a stick on the ground that I have no clue. There are so many things that could go wrong there. I’ve been reading some really interesting thoughts about even some aggressive thoughts that this might be the time to really change regimes in Iran and for the US to have a bit more of an aggressive stance. I really don’t have a perspective. Obviously, there’s a lot at stake there. Then, if we talk about the other parts, Greenland, I will not opine too much on. Maybe we’re done for now. Maybe there’ll be some other concessions to the US that weren’t already there in the ’50s. Taiwan, I won’t bet either. I’m sad to say I think it might happen at some point in time, but I’m not sure when and what would drive it. Last but not the least, Venezuela is my only really negative prediction. I feel it will continue to be a significant dictatorship as it was before managed enough by other people with the difference now that it has a tax to be paid to the US in the form of oil of some sort, etcetera, and maybe gas, maybe other things as well that it didn’t have before. That’s probably my most negative prediction for the coming year on the geopolitical side. Bertrand Schmitt Without going into detail, I would mostly agree with what you shared. At least that makes sense. But as we know, it’s not always what makes sense, but what might happen. I can tell you 100% I would not have guessed this operation against Maduro. This was so well done, well executed, and shocking at the same time that it’s… I think it shows that it’s hard to guess some of this stuff because there are certainly some new ways to wage limited war, for instance. So it’s certainly interesting, and we certainly need to get used to pretty bombastic statements. But for Venezuela, I don’t think it can be worse than what it was before. I’m probably more optimistic that gradually it can get better. Nuno Goncalves Pedro Just to put perspective on why we’re not making predictions on some of these elements, I think this is a funny story, but I was in Madeira. Actually, first time I was in Madeira, although I’m originally from Portugal. I’ve never been to the islands. Obviously, as you guys know, or some of you might know, there’s a lot of connection between Madeira and Venezuela. There’s a lot of immigration from Madeira Islands to Venezuela. One of my Uber or Bolt drivers there in Madeira was Venezuelan. Was born in Venezuela, but Portuguese descent, et cetera. He was telling me this was still last year. Late last year. Because I told him I lived in US, et cetera, and he was like, “Oh, hopefully, Trump will get Maduro out of there.” In my mind, I was like, “Dude.” No disrespect to the gentleman, but it’s like, “Okay. Mike, your perspective on geopolitics is maybe a little bit exaggerated.” And a couple of days later, we know what happened. When geopolitical decisions are better predicted by some probably very astute Uber drivers, you’re like, “Maybe I shouldn’t make a bet. I have no clue what’s going to happen, no clue what’s going to happen in Greenland, et cetera.” Anyway, a couple of predictions on that element. Bertrand Schmitt That’s why it’s so right. You have to be careful with the prediction, but it doesn’t remove the fact that I think nations and companies that have to play a global game have to understand in some ways what is the game, what are the powers in place, what could happen potentially, but also be realistic. Not be about wish and dreams, but more about, what’s the power relationship? Who has the money? Who has the means? Who has the capacity to do this or that? Because if you start that way, at least the scope of what’s possible, what’s reasonable is more and more clear more quickly. Some stuff like happened with Maduro, I would never have predicted, but for sure, if there’s one country that can do this sort of stuff, it’s the US. I’m not sure anyone has a technology and the means in terms of support infrastructure to do something like this. It’s tough to predict what will happen a year from now for any specific country, but I think that even trying to get a better understanding about the forces in play and their capacity and understanding and accepting that at some point, it’s all about real politic and relationship of power, the more your eyes would be wide open about what’s possible versus simple, wishful thinking. Nuno Goncalves Pedro Fintech, Crypto and Frontier Tech Moving maybe to our last section around fintech, crypto, and frontier tech. For me, just two very quick predictions, views of the world. I think on the frontier tech side, I won’t make a prediction. I will just tell you all to go and listen to our episodes, the one on infrastructure, which is immediately prior to this one, and the episodes that we’ve had around a couple of other topics including AI, what’s the future of your children, because I think they illustrate a lot of the points that we’re seeing and manifesting themselves over the next year and over the next 2 or 3 years as well beyond that. I feel those tomes are complete in and out of themselves, so you can just go and listen to them. Then my second comment is on crypto. I feel crypto has become of the essence, particularly under the current administration in the US, very favored. Obviously, we are now in a world where crypto is just part of the economic system, and I think we’ll see more and more of that emerging, and in some ways, crypto is becoming mainstream. Question is what blockchains will be the blockchains of the future? Obviously, there’s a bunch of bets put out there. We, ourselves, as Chamaeleon, have one investment in one of the significant bets in the space. But besides that, who’s going to win or not, we feel that we’re past the crypto winter. It’s now mainstream days, and we’ll see a lot more activity in there. Bertrand Schmitt I must say with crypto, I’m a bit confused. As you say, we are past the crypto winter. There is much less uncertainty in regul

This week, Marianna sits down with John Faragon to talk about injectable PrEP and drug interactions. Tune in to learn about the current options for injectable PrEP, how the medications are metabolized, and more. -- Resources mentioned in this episode: NECA AETC Mobile Apps: https://www.necaaetc.org/mobile-appsHIV ART Drug Interactions Guidelines: https://www.hivguidelines.org/guideline/hiv-art-drug-interactions/HIV Drug Interactions Checker: https://www.hiv-druginteractions.org/checker--Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

As fleets enter 2026 with cautious optimism, they are applying lessons learned from the downturn in order to stay competitive. From strategy shifts to investing in modern TMS platforms, automation, and AI, this discussion highlights the priorities and operational changes fleets are focused on this year. Fleet leaders will gain practical guidance on where to focus, what to measure, and how to adapt for the year ahead. FOR MORE INFORMATION: https://pcssoft.com/ WANT TO RESPOND TO THIS EPISODE? Call our Dialog Line: 888-878-3247 DOWNLOAD THE NEW INBOUND LOGISTICS APP featuring the updated and expanded Logistics Planner! Available on iTunes and the Google Play Store: bit.ly/ILMagApp  bit.ly/ILMagAppGoogle Are you a #logistics Thought Leader that would like to be featured on the Inbound Logistics Podcast?  Connect with me on X:  @ILMagPodcast Email me: podcast@inboundlogistics.com   Connect with Inbound Logistics Magazine on LinkedIn: https://www.linkedin.com/company/inbound-logistics Follow us on X: www.twitter.com/ILMagazine Like us on Facebook: www.facebook.com/InboundLogistics Catch our latest videos on YouTube: www.youtube.com/inboundlogistics   Visit us at www.inboundlogistics.com

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

In Ephesians, Apostle Paul calls us to be as beloved children of God, imitating God. We are to walk in love, as Christ loved us, to watch what we speak and how we define ourselves, and to be aware of the direction of our lives and what outcomes it's leading to.--To hear more messages from The Image Church, subscribe to our podcast or YouTube channel. Also follow us on social media (Facebook and Instagram) or download our Image Church app in the App Store and Google Play Store to learn more about us and stay up to date.

We've seen greatness and not-so-greatness over the first two weeks of the season. Perhaps the real test will be against a team FC Cincinnati has managed to best even during their absolute lows. Toronto FC come into town with two difficult losses under their belt, but they need one more road tilt before their home opener. The Reds have managed to clear their books of two difficult contracts, only to pull in Josh Sargent, the American striker Cincinnati had been pursuing in the past. We talk with Jeffrey from the Toronto 'Til I Die podcast to get his thoughts on the second year under head coach Robin Fraser. How does this squad operate under some of the U.S. national team's bigger pieces? And speaking of national teams, how do things look in the Great White North with the World Cup on the horizon? Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

In this episode of the show Gary discusses the true costs associated with electric vehicles and debunks common myths surrounding their affordability.He highlights the CODE Report indicating that many consumers are deterred from purchasing EVs due to perceived high upfront costs, limited range, and expensive battery replacements.However, he presents data showing that the majority of EV owners actually save money over time, especially those with home charging capabilities. The conversation emphasizes the importance of education in changing public perception about EV pricing and ownership.TakeawaysExpensive upfront costs deter many from choosing EVs.Limited range and battery replacement costs are common concerns.Education is crucial in countering misconceptions about EVs.80% of people save money by switching to EVs.Home charging significantly increases savings with EVs.Public charging costs can affect overall savings.Used EVs often provide better value than ICE vehicles.Many consumers have never driven an electric vehicle.The cost of running an EV is significantly lower than ICE cars.Pre-registered EVs can be found at substantial discounts.Key Sound bite"The average saving is £5,850 with an EV."Chapters00:00 The Cost of Electric Vehicles: An Overview05:09 Understanding Savings with Electric Vehicles07:02 CODE Quotes08:01 What do other sources say11:22 Debunking Myths: Education on EV Costs12:41 Recent pricing Examples15:16 Dealer Preregistrations16:28 Conclusion: The Future of EV AffordabilityThe EV Musings Podcast is sponsored by Zapmap, the go-to app for EV drivers, helping you find and pay for public charging with confidence.Links in the show notes:The Cost of Driving Electric (CODE) ReportPetrol and diesel buying intent rises despite BEV growth | EY - UKAverage range of new electric cars now 300 miles | Electrifying.comEpisode produced by Arran Sheppard at Urban Podcasts: https://www.urbanpodcasts.co.uk(C) 2019-2026 Gary ComerfordSupport me: Patreon Link: http://www.patreon.com/evmusingsKo-fi Link: http://www.ko-fi.com/evmusingsThe Books:'So, you've gone electric?' on Amazon : https://www.amazon.co.uk/dp/B07Q5JVF1X'So, you've gone renewable?' on Amazon : https://amzn.to/3LXvIckSocial Media:EVMusings: Twitter https://twitter.com/MusingsEvInstagram: @EVmusingsOctopus Energy referral code (Click this link to get started) https://share.octopus.energy/neat-star-460Upgrade to smarter EV driving with a free week's trial of Zapmap Premium, find out more here https://evmusings.com/zapmap-premiumMentioned in this episode:ZapmapThe EV Musings Podcast is sponsored by Zapmap, the go-to app for EV drivers, helping you find and pay for public charging with confidence. Zapmap is free to download and use, with subscription plans for enhanced features such as using Zapmap in-car on CarPlay or Android Auto, and discounted charging across thousands of charge points. Download the app from the Apple App Store or Google Play Store or find out more at www.zapmap.com.Zapmap EV Guide

On The Bruce Collins Show, Bruce interviews Brent Dusing, CEO of TruPlay Games (www.TruPlayGames.com), for an in-depth discussion on faith-based gaming, Christian media platforms, digital free speech, Big Tech bias, app store policies, content moderation, religious discrimination, Google Play Store restrictions, TikTok algorithm visibility, Christian entrepreneurship, family-friendly gaming, values-driven entertainment, online censorship, Section 230 debates, platform transparency, tech industry accountability, and the future of Christian content in the digital marketplace. Are major tech platforms like Google and TikTok suppressing Christian voices, or is this a broader issue of algorithmic moderation and marketplace competition? This compelling conversation explores religious liberty, digital rights, culture and technology, and the intersection of faith and Silicon Valley in today's rapidly evolving online ecosystem.

Time to break out the winter scarves for this weekend's first big away trip to the chilly confines of Saint Paul. FC Cincinnati makes another heralded trek to Minnesota United, hoping to stitch multiple solid performances together. The Orange & Blue have left their history in the past, winning their last two visits to Allianz Field and leaving all memories of their worst loss ever in the snowdrifts. As much as Cincinnati has kept their roster primarily constant in the offseason, the Loons have endured a very turbulent winter with a roster that looks quite different. The promise of superstar James Rodrigues has been tempered with the uncertainty of new head coach Cam Knowles, but the first match at least brought a point back to their home opener. We talk with Dan from The Loony Bin Podcast to analyze the roster shifts and expectations. Can Minnesota alter the trend of Cincinnati taking the wins? Will we hear "Wonderwall" or "Mr. Brightside" after 90 minutes? Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Bill Reno is back with a new season of  "Gloves Off" where he takes an unfiltered look at the game with candid conversations w/ former GK's.  This week Bill is joined by Dr. Bill Steffen. The Two discuss his  college career, the mindset of the GK, and how the origins of the ACC Powerhouse Programs.   Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 More Info on All our shows at www.theuniongk.com *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr Mary Talley Bowden joins The Jeff Dornik Show to break down her legal battle against the Texas Medical Board after it issued a public reprimand for her good faith effort to administer Ivermectin to a dying COVID patient under a court order. The Board ignored medical expert testimony, disregarded due process, and punished her despite her reliance on judicial authority and legal counsel. Attorney General Ken Paxton has now intervened to defend Dr Mary Talley Bowden's constitutional rights and refuse representation of the Texas Medical Board in her case. The discussion also examines RFK Jr's first year leading HHS, the reality of MAHA, and the continued presence of COVID shots on the market amid reports of disease, disability, and death without accountability.SPONSORSupermassive Black Coffee is crafted from organic, gourmet beans fire-roasted in an antique Victorian-era roaster, delivering the rich, smooth, non-acidic taste that reminds you this is how coffee was always meant to be. Use code JEFF50 for 50% off your first order. https://supermassiveblackcoffee.com/?ref=JEFFFollow Dr Mary Talley Bowden on Pickax - https://pickax.com/mdbreatheFollow Jeff Dornik on Pickax - https://pickax.com/jeffdornikTune into The Jeff Dornik Show LIVE daily at 1pm ET on Rumble. Subscribe on Rumble and never miss a show. https://rumble.com/c/jeffdornikPickax is officially live, and we are building what Big Tech refused to build, a platform where creators own their voice, their audience, and their future without algorithms manipulating reach or silencing truth. Download Pickax today in the Google Play Store and Apple App Store and join a movement where technology serves people, freedom, and real human connection. https://pickax.com/?referralCode=y7wxvwq&refSource=copy

Dr. Lakshmi Rajdev and Dr. Manish Shah join the podcast to discuss the updated guideline on immunotherapy and targeted therapy in unresectable locally advanced, advanced, or metastatic gastroesophageal cancer. They share first-line and subsequent-line recommendations for both gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma based on actionable biomarkers including PD-L1 expression, MMR and/or MSI, CLDN18.2 expression, and HER2 status. They note the importance of the algorithms and tables in the guidelines that provide visual illustrations and quick reference guides of the evidence-based recommendations. They also comment on ongoing and recently presented trials that may impact future guidelines in this space. Read the full guideline, "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update" at www.asco.org/gastrointestinal-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/gastrointestinal-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02958      Timestamps ·       00:00 – 02:15 Introduction and Overview ·       02:16 - 08:20 First-line treatment for patients with pMMR/MSS, HER2-negative gastroesophageal adenocarcinoma ·       08:21 –10:29 First-line treatment for patients with pMMR/MSS, HER2-positive gastroesophageal adenocarcinoma ·       10:30 – 14:39 First-line treatment for patients with dMMR/MSI-H, gastroesophageal adenocarcinoma ·       14:40 – 18:03 First-line treatment for ESCC ·       18:04 – 22:04 Second- and third-line therapy for gastroesophageal adenocarcinoma and ESCC ·       22:05 – 24:38 Importance of guideline ·       24:39 – 27:45 Outstanding questions and future research   Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Lakshmi Rajdev from the Icahn School of Medicine at Mount Sinai and Dr. Manish Shah from Weill Cornell Medicine, co-chairs on "Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update." Thank you for being here today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you for having us. It is wonderful. Brittany Harvey: And then just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Rajdev and Dr. Shah, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then to dive into what we are here today to talk about, Dr. Shah, I would like to start first with what prompted the update to this guideline, which was previously published in 2023, and what is the scope of this updated guideline? Dr. Manish Shah: Yes, terrific. So even in the last few years, the pace of drug development in gastroesophageal cancers has just been astounding. So, what prompted this guideline is actually the practice-changing results for a new biomarker, CLDN18.2 hat was based on the GLOW and SPOTLIGHT studies, as well as a practice-changing study in HER2-positive disease where we added pembrolizumab to trastuzumab and chemotherapy for tumors that are HER2-positive and PD-L1 CPS 1 or greater. And then there were also new studies and new approvals in esophageal squamous cell cancer that you will hear about as well. So there were several studies, overall more than 5,000 patients were reported on, and that led to several new therapies, new indications, and it really necessitated this guideline. Brittany Harvey: Excellent. It is great to hear about all of these exciting updates in this space. So then to next review the key recommendations of this guideline by clinical question that the expert panel addressed. So, Dr. Rajdev, what is the recommended first-line treatment for patients with proficient mismatch repair, microsatellite stable, HER2-negative gastroesophageal adenocarcinoma? Dr. Lakshmi Rajdev: Thank you for that question. So historically, we have sort of used fluoropyrimidine and platinum doublets, which yielded a survival of about one year. More recently, immunotherapy and targeted therapy options have improved outcomes in patients with advanced esophageal and gastric adenocarcinoma, as well as squamous cell carcinoma. Patients with gastric and GE junction adenocarcinoma have a high rate of actionable alterations, so it is imperative that physicians test the following biomarkers upfront so that it can help guide therapy. The markers recommended by the ASCO panel are HER2, MMR or MSI, CLDN18.2, and PD-L1. And also, it was recommended to use NGS if feasible in this patient population. HER2, as we know, is expressed in about 15% to 25% of patients; PD-L1 expression occurs in about 80% of patients; MSI-high, deficient MMR is present in about 5% to 8% of patients; and CLDN18.2 expression is present in about 40% of patients. There is, of course, biomarker overlap. About 13% to 22% of CLDN18.2 patients are also PD-L1 positive. For patients with pMMR or microsatellite stable HER2-negative disease with PD-L1 expression greater than 1 and absence of CLDN18.2, the panel recommended a first-line therapy with fluoropyrimidine and platinum-based therapy in combination with immunotherapy. These recommendations stem from large phase 3 trials, and the agents approved in the United States are pembrolizumab, nivolumab, and tislelizumab. It has been shown that immunotherapy benefit is greater in patients with higher PD-L1 expression, and it is not possible to comment on the individual PD-L1 cutoff scores and sort of identify the optimal PD-L1 cutoff score that sort of balances benefits and harms. But what is recommended is that immunotherapy-based treatments can be offered in patients with a CPS score of greater than 1. With regard to the choice of immunotherapy agents, that is pembrolizumab, nivolumab, or tislelizumab, these agents are considered to have similar efficacy, and the selection of an agent could be based on dosing schedule, cost considerations, toxicity, and the method of administration. Typically, clinicians should avoid withholding the start of chemotherapy while awaiting biomarker testing, depending on the clinical scenario. Now, for patients with pMMR microsatellite stable disease that is HER2-negative with PD-L1 expression less than 1 and positive CLDN18.2 expression, zolbetuximab-based treatments or in combination with chemotherapy is recommended, and this is based on two global phase III randomized controlled trials, the GLOW and the SPOTLIGHT. And across both studies, the hazard ratio for the overall survival was 0.78, and similarly, there was also an improvement in progression-free survival favoring the zolbetuximab group compared to the chemotherapy group alone. An important note is that nausea, vomiting is commonly associated with zolbetuximab-based treatments, and the panel recommended prophylactic antiemetics, adjusting zolbetuximab infusion rates, pausing infusion temporarily, using non-prophylactic antiemetics, and hydration intravenously prior to discontinuation of zolbetuximab-based chemotherapy. So effective handling of the GI-related symptoms with zolbetuximab is recommended prior to discontinuation of therapy. Now, for patients with pMMR microsatellite stable HER2-negative gastric, GE junction adenocarcinoma with PD-L1 expression greater than 1 and CLDN18.2 positivity, the ones with the dual expression with CLDN18.2 as well as PD-L1 chemotherapy, the choice of therapy can be based on the degree of PD-L1 expression, the toxicity profile, the burden of symptoms, and the anticipated improvement in symptoms associated with response to treatment, the patient comorbidities, the prior medical and treatment history. So this decision needs to be made on a case-by-case basis, and these are some of the factors that we suggested that could potentially influence the choice of therapy. For patients with pMMR microsatellite stable disease that is HER2-negative and a PD-L1 expression less than 1 and an absence of CLDN18.2 expression, first-line therapy with fluoropyrimidine and platinum-based chemotherapy is recommended. So you can see we have segmented out patients based on PD-L1 expression, pMMR and microsatellite stable disease expression, and also based on CLDN expression. Brittany Harvey: Absolutely. And that first point you noted, I think is really important, that biomarker testing is really critical for treatment decision-making in this space. So then the next subgroup of patients that the panel looked at, Dr. Shah, what first-line therapy is recommended for patients with proficient mismatch repair, microsatellite stable, HER2-positive gastroesophageal adenocarcinoma? Dr. Manish Shah: So this was an update from a few years ago. So we have known for 15 years now that if you are HER2-positive, you should get trastuzumab plus chemotherapy. That was based on the ToGA trial. And the update now is based on a trial called KEYNOTE-811, where it examined the addition of pembrolizumab to trastuzumab and chemotherapy versus trastuzumab and chemotherapy, and there was a progression-free and overall survival benefit. And again, here, the biomarkers are important. If your CPS PD-L1 is less than 1, we would not recommend Pembrolizumab in that setting, so you would still get trastuzumab and chemotherapy. But if it is 1 or greater, the PD-L1 CPS score, then we do recommend pembrolizumab unless there is a contraindication to immunotherapy. The take-home message really is from the onset of diagnosis, please check your biomarkers. And I will just, it is worth repeating, it is important to check your PD-L1 status, HER2 status, mismatch repair status, and CLDN18.2 status. And then the optimal therapy, and it is outlined in the publication, is really biomarker-driven. We know that if we are able to hit the target that is overexpressed, we are going to have a better outcome. And Dr. Rajdev did mention where there is overlap, there can be a lack of data, and that is where we are with both PD-L1 positive and CLDN positive. Here we do have data in HER2-positive cases where if you are both HER2-positive and PD-L1 positive, you would combine trastuzumab and pembrolizumab for the best outcomes. Brittany Harvey: Understood. I really appreciate you detailing what is most important for each individual biomarker combination that patients may have. So then following that, Dr. Rajdev, what does the expert panel recommend for first-line treatment for patients with esophageal squamous cell carcinoma that is not amenable to definitive chemoradiation? Dr. Lakshmi Rajdev: There are three phase III randomized clinical trials that have influenced practice in patients with esophageal squamous cell carcinoma examining the benefit of immunotherapy in this patient population. The RATIONALE-306 was a randomized trial of tislelizumab plus chemotherapy with platinum and fluoropyrimidine or paclitaxel versus placebo with chemotherapy. And then you have the KEYNOTE-590, which compared pembrolizumab plus chemotherapy versus chemotherapy alone. And then you have CheckMate-648, which included comparisons of nivolumab plus chemotherapy versus nivolumab plus ipilimumab or chemotherapy. And the primary endpoints for these studies were overall survival, and they did look at subgroups with PD-L1 expression. They used TPS score greater than 1% in CheckMate-648 and PD-L1 CPS greater than 10 in KEYNOTE-590. The bottom line is that the overall hazard ratio for overall survival across this patient population was 0.72. So clearly, there is benefit in patients that express PD-L1 CPS greater than 1 for benefit for the addition of immunotherapy. Now, the benefit again in patients with a PD-L1 expression less than 1 remains limited, and so the panel has made a recommendation for using immunotherapy in combination with platinum-based chemotherapy in patients with a PD-L1 greater than 1. Again, we know that it is hard to make recommendations on what PD-L1 cutoffs are recommended in this patient population, meaning that should it be limited to patients with a PD-L1 of 1 to 4 or greater than 10? I think that the general consensus that has been gleaned from the data is that the higher the PD-L1 expression, the greater the benefit. I do want to comment on another option that is available in patients with squamous cell carcinoma compared to adenocarcinoma, and that is the combination of nivolumab and ipilimumab. Now, in CheckMate-648, nivolumab with ipilimumab was also recommended as a treatment option in patients that have a PD-L1 score of greater than 1. There was a survival benefit demonstrated with this combination compared to chemotherapy alone. And an important observation in this study is that, although there was a slightly increased rate in early death, but there was really no significant difference in PFS and OS compared to chemotherapy alone. Importantly, the treatment appeared to be pretty well tolerated by the study population. There was a notable difference in the objective response rate, which was 35% in the nivolumab plus ipilimumab group compared to patients receiving nivolumab and chemotherapy, where it was 53%. So superiority is, so the importance of chemotherapy in patients with esophageal squamous cell carcinoma is to be noted. However, there is no difference in overall survival and progression-free survival when using the combination of nivolumab and ipilimumab, and thus it affords a chemotherapy-free option for this patient population with esophageal squamous cell carcinoma and a CPS with a score of greater than 1. Brittany Harvey: Understood. I appreciate you reviewing the evidence underpinning those recommendations as well. So then the next patient population that the guideline panel addressed, what first-line therapy is recommended for patients with deficient mismatch repair, microsatellite instability-high, gastroesophageal adenocarcinoma or esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: The rate of MSI-high expression is about 3% to 7% across different studies. Now, the KEYNOTE-158 was a tumor-agnostic study in patients with non-colorectal cancers, and again, the problem with the MSI-high population, given that it is so rare, the numbers in the individual studies are fairly small. But consistent outcomes do emerge, indicating high response to immunotherapy. So in KEYNOTE-158, a response rate of about 46% was noted. The number of patients was small, it was about 24. In CheckMate-649, which is a study of chemotherapy plus or minus nivolumab in patients with advanced gastric adenocarcinoma, there was again a very small number of patients, and patients that were MSI-high or deficient MMR did experience substantial benefits with the addition of immunotherapy, with hazard ratios in the order of about 0.38. In KEYNOTE-062, again, it was a very small number of patients, again about 6% or so, and similar to CheckMate-649, a substantial benefit was noted in combination with chemotherapy, but also there were benefits noted with pembrolizumab alone. The RATIONALE-305 again was a study of tislelizumab in combination with chemotherapy and similarly showed benefits to the combination of chemotherapy plus immunotherapy in this patient population. I think that we are all aware of the dramatic benefits of immunotherapy in this particular subset of patients, deficient MMR MSI-high, and also we have seen in CheckMate-649 they did have a subset of patients that received nivolumab and ipilimumab. And in this patient population, they noted unstratified hazard ratio of 0.28. So I think that the overall consensus is that immunotherapy is a very important treatment modality in patients with deficient MMR MSI-high disease, given that a lot of the trials in gastroesophageal adenocarcinoma have utilized chemotherapy-based options, that is certainly a recommendation of the panel to use chemotherapy in combination with immunotherapy. However, on a case-by-case basis, the panel recommended immunotherapy alone as well, and given the high response rates noted in trials across different diseases as well as noted in this disease as well. Brittany Harvey: Certainly. And I appreciate you both for reviewing these first-line recommendations. So moving to later lines of therapy, Dr. Rajdev, what recommendations did the expert panel make for second or third-line therapy for gastroesophageal adenocarcinoma and esophageal squamous cell carcinoma? Dr. Lakshmi Rajdev: So, I think that the RAINBOW trial that investigated the utility of the addition of ramucirumab as second-line therapy has been around since 2014, and those results have led to the addition of ramucirumab to taxane-based therapy in the second-line setting. Based on the utilization of oxaliplatin and platinum-based therapy in the front-line setting, there may be patients that have an underlying neuropathy, and so we wanted to really include treatment options for this patient population so that an agent that is less neurotoxic could also be recommended in combination with ramucirumab. The RAMIRIS trial is one such trial where ramucirumab was combined with FOLFIRI, and it demonstrated benefit in combination with ramucirumab. So we have listed that as a potential treatment option for patients in the second-line setting who may have an underlying neuropathy or even for whatever reason that based on the toxicity profile, that needs to be the preferred option by a physician, that recommendation is new from the older guidelines that we have. With regard to the utility of PD-1 inhibitors, there really has been no benefit noted in the second-line setting with regard to overall survival or progression-free survival, so no recommendation is made for that option. I think an important study that has been recently presented is the DESTINY-Gastric04 trial, which really has been practice-changing and has led to the recommendation for trastuzumab deruxtecan in patients that have HER2-positive metastatic gastric or GE junction adenocarcinoma. Now, this is a phase III trial in patients who retained HER2-positive disease after progressing on front-line trastuzumab-based treatments, and the comparator for this trial was trastuzumab deruxtecan versus ramucirumab plus paclitaxel. There was significant improvement and progression-free survival in patients that received trastuzumab deruxtecan. The patients that were excluded from the trial are patients that have pulmonary problems, interstitial lung disease; that is one of the toxicities of this particular agent, and close monitoring and prompt initiation of therapy such as glucocorticoid treatment in patients who develop this toxicity was also highlighted by the panel. So to summarize, the new guidelines highlight the possibility of FOLFIRI plus ramucirumab as a second-line option and then trastuzumab deruxtecan as a later-line option in patients that still retain HER2 expression. And that is very important because the trial did retest patients whether they expressed HER2. As we know, in a substantial number of patients, there is downregulation of HER2, and there is emerging data that the benefit for subsequent HER2-directed therapies is best noted in patients that still retain HER2 expression. Brittany Harvey: Great. So as our listeners have heard, there are many recommendations and new treatment options for advanced gastroesophageal cancer. Dr. Shah, earlier you highlighted the importance of biomarker testing, but I would like to hear in your view, what is the importance of this guideline and how will it impact both clinicians and patients with gastroesophageal carcinoma? Dr. Manish Shah: So as we have discussed throughout this podcast, the treatment for gastroesophageal cancer, both adenocarcinoma and squamous cell cancer, is increasingly complex, increasingly biomarker-driven. And I think the value of the guideline is to place all of that into context. So it provides the data for why certain biomarkers are important, what therapies should be indicated. Not only that, but if you are able to review the guideline, it provides the details of each of these studies and summarizes them in a meta-analysis fashion to sort of give you the context, because sometimes the individual studies can be maybe a little bit discordant or confusing and the guideline attempts to harmonize all that. And then also, I think the tables are very, very interesting because they give you actual numbers in terms of how many patients over a thousand would this benefit or how many patients over a thousand would this cause harm in terms of nausea, vomiting, or other things like that. So it gives you context for helping clinicians and patients weigh the potential benefits of the novel treatment strategies against the potential adverse events. And then finally, the guideline does also provide an algorithm that you are able to follow based on the biomarkers, and those are in figures 4 and 5. So I think overall, it is a very comprehensive guideline. It intends to make more manageable a very complex subject, and you know, I really encourage our listeners to review it after listening to the podcast. Dr. Lakshmi Rajdev: If I can add to that, I think that what is also really good about the guidelines is there are quick summaries. So if someone is busy in the clinic, of course, there is the opportunity to review the data supporting the guidelines in great depth in the manuscript, but what is also really good is that there are good summaries. In the event that you are very busy, you can easily identify what the recommendations should be for that particular patient based on these summaries. Brittany Harvey: Absolutely. Listeners are encouraged to review the full guideline, including those tables and figures that may be more helpful when they are looking for something quick to look at in the clinic as well. So, as you both mentioned, there have been a number of recent practice-changing trials in this area. So I imagine there is still a lot of ongoing research as well. So Dr. Shah, what are the outstanding questions regarding treatment options for patients with locally advanced unresectable, advanced, or metastatic gastroesophageal carcinoma? Dr. Manish Shah: I think we touched upon it a little bit. The guidelines are based on the data available, and they are primarily examining one novel therapy with chemotherapy in a specific biomarker population. But as you know, the biomarkers are not either/or; you are not either CLDN18.2 positive or PD-L1 positive. A portion of patients could have dual biomarkers, and you know, I think that we are generating data on how to manage those patients. At the recent GI Symposium in January this year, the ILUSTRO trial was presented by Dr. Shitara, which looked at combining zolbetuximab and chemotherapy with immunotherapy for dual-positive biomarkers, and that is leading to a phase III study that has begun to enroll. So unanswered questions are: how do we manage dual-positive biomarkers? The other thing that was mentioned is that the current data for mismatch repair deficiency involve chemotherapy plus immunotherapy. Only squamous cell cancer is there a study with a positive non-chemotherapy kind of backbone, that is CheckMate-648 that Dr. Rajdev mentioned. As we move forward, it will be good to get data on non-chemotherapy options in certain biomarker-positive populations. And then finally, another update, which is likely to be practice-changing, is the HERIZON-GEA-01 study that looked at zanidatamab, which is another biparatopic antibody that targets HER2, and that is likely to change practice. And as that data gets published, we may look to even do a rapid update for the current immunotherapy and targeted therapy guideline that is just being published. Dr. Lakshmi Rajdev: So, if I can add to that, there are numerous ADCs that look very interesting. There are bispecific antibodies; in fact, the zanidatamab is a bispecific antibody showing improved activity in patients with HER2-positive disease. So I think there are studies from Asia looking at CLDN CAR T-based therapies. So, I think that there are a lot of novel agents and a lot of excitement in the field. We know that the bemarituzumab study, unfortunately, the FGFR2 inhibitor failed to demonstrate any benefit, but I think that there are other agents that are being explored, so there are newer targets, newer agents, ADCs, bispecifics that could potentially change the field in the future. Brittany Harvey: Yes, we will look forward to the data to address these unanswered questions and new agents and inform future guideline updates. So, I would like to thank you both for all of your work to review the evidence here and update this important guideline, and for your time today, Dr. Rajdev and Dr. Shah. Dr. Lakshmi Rajdev: Thank you. Dr. Manish Shah: Thank you. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/gastrointestinal-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Dr. Bishal Gyawali and Dr. Tessa Cigler share the new, comprehensive, evidence-based update of the ASCO guideline on the use of hematopoietic colony-stimulating factors in patients with cancer. They discuss recommendations on primary prophylaxis, secondary prophylaxis, and treatment of febrile neutropenia along with stem cell mobilization, efficacy, safety, duration, dosing, and administration of CSFs – including biosimilars. They highlight where it is appropriate to use a CSF, and importantly, when not to use a CSF. They touch on the significance of individual patient considerations and cost implications, and future work to refine the risk factors for the development of complications of febrile neutropenia. Read the full guideline, "White Blood Cell Growth Factors: ASCO Guideline Update" at www.asco.org/supportive-care-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/supportive-care-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02938     Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Bishal Gyawali from Queen's University in Kingston, Ontario, Canada, and Dr. Tessa Cigler from Weill Cornell Medicine in New York, New York, co-chairs on "White Blood Cell Growth Factors: ASCO Guideline Update." Thank you for being here today, Dr. Gyawali and Dr. Cigler. Dr. Bishal Gyawali: Thank you very much for having me. It's a pleasure. Dr. Tessa Cigler: Hi there. Nice to be here as well. Brittany Harvey: Great. And then before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Cigler and Dr. Gyawali, who have joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then I'd like to dive into the guideline that we're here today to talk about. So first, what prompted an update to this guideline on the use of hematopoietic colony-stimulating factors in patients with cancer, and what is the scope of this updated guideline? Dr. Bishal Gyawali: The last version of the guidelines from ASCO on this topic was back in 2015, so it has been more than a decade since ASCO had a guideline on the use of G-CSF in patients with cancer receiving treatment. So it was due for an update because there has been a lot more evidence based on not necessarily new drugs, but evidence for proper timing of these agents and the duration of these agents, as well as there have been a lot of new biosimilars, and there are questions about are these biosimilars equivalent or how do we choose among these different options. One is that content of the evidence that has evolved over time in the last decade, but also I think the last time we had these guidelines, the ASCO guidelines were not incorporated to have those evidence GRADE tables. So the quality of the ASCO guidelines itself has evolved over the years, so we wanted to have a new version of the guideline that includes not only the new evidence, but also contains those evidence GRADE tables that will help to quantify the benefits. And so I think it was high time, and even more than that, the newer ASCO guidelines for any guideline, they also include considerations of cost, access, equity, and all these factors that were not included in the previous version of the guideline. So I think it's only natural that with time the guideline should also evolve. Dr. Tessa Cigler: I agree completely, and just as a framework, as we all know, neutropenia and its complications, including febrile neutropenia and infections, are still an important toxicity of many myelosuppressive chemotherapies. And these neutropenic complications do require prompt evaluation and treatment and often hospitalization, and we know that hematopoietic colony-stimulating factors, which I'm going to refer to as growth factors, can reduce the duration and severity of neutropenia and the risk of febrile neutropenia, so it remains an important topic in the practice of clinical oncology. Brittany Harvey: Absolutely. It's an important topic for both clinicians and for patients who are receiving treatment for their cancer. And as you said, there was a substantial amount of literature to review here and updating everything to be in line with the GRADE evidence rating system, so there was a lot of work that you both put into this. So then next, I'd like to review the key recommendations of this guideline by clinical question. So first, what factors did the expert panel identify that should influence the decision to administer primary prophylaxis of febrile neutropenia with a CSF? Dr. Bishal Gyawali: Yeah, so I think that constitutes one of the most important recommendations in our guidelines about primary prophylaxis with G-CSF. And this is important because not only it's about when to use it, it's also about when not to use it, as in the ASCO "Choosing Wisely" campaign has also made some recommendations about this. So our guideline recommendations are also aligned with that. So first of all, we recommend that primary prophylaxis with G-CSF is recommended when the risk of febrile neutropenia because of the chemotherapy regimen is equal to or more than 20% unless an alternative chemotherapy regimen with comparable efficacy and safety that does not need G-CSF is available. And the quality of evidence to make this recommendation is high, so we give a strong strength of recommendation for this. Having said that, even for patients where the risk of febrile neutropenia is not necessarily 20%, it's a little lower, but because of other patient-related factors, the patient is at a higher risk of complications from febrile neutropenia, such as age, comorbidities, and other factors, in such case primary prophylaxis with G-CSF should be offered. And we also make a recommendation that if G-CSF is not affordable or available, then antibiotic prophylaxis can also be offered, but the evidence quality for this is low, and the strength of recommendation is very conditional. A couple of things to highlight here would be that, I think Dr. Cigler can attest to that, we ran into lots of problems about finding the data for the evidence base to say what are the patient-related factors that actually make them at a higher risk of febrile neutropenia, you know, like how did that 20% benchmark come about? Why 20%? Or when we say even if it's less than 20%, if based on other comorbidities, if the risk is higher, we tried to dig into that evidence. For example, we're talking about our "Box 1" in the guideline, what is the evidence for each item we have included under that "Box 1"? And we tried to do a lot of search to find the evidence for that, and some of them do have strong evidence, and that will tie into our future research ideas as well. And some of them actually don't have such solid evidence too, so that was one of the reasons why we ran into lots of problems about how do we quantify whether someone is at a high risk of febrile neutropenia and where that 20% benchmark comes from. Dr. Tessa Cigler: And definitely, because there's not very clear data, our guidelines definitely leave room for physician discretion in all these situations. Brittany Harvey: Absolutely. I find that in a lot of these guidelines the key point is that there's a lot of shared decision-making with patients after talking through what risk factors they may have and what is best for them in their individual clinical scenario. So then moving on to secondary prophylaxis, what factors did the expert panel identify that should influence the decision to administer secondary prophylaxis of febrile neutropenia with a CSF? Dr. Tessa Cigler: So for patients who've already experienced a neutropenic complication from a previous cycle of chemotherapy, the question is which patients should then receive prophylactic G-CSF for subsequent cycles of chemotherapy. And without a lot of evidence again to guide us, the panel really felt strongly that secondary prophylaxis should be used when a treatment delay or when a reduced dose of chemotherapy would be thought to compromise cure rates or survival outcomes. We do note that in many situations, certainly a dose reduction or a delay would be a very reasonable alternative or an additional strategy to G-CSF administration. Dr. Bishal Gyawali: Yeah, I think it's more like if there is going to be compromise in outcomes without using G-CSF, as in if we can't maintain the dose intensity and that's going to lead to inferior outcomes, then we should. But if we can reduce the dose intensity and treatment frequency and still have the same outcomes, then I guess in simple words, we're just trying to say use it when it's absolutely needed, or you can also look into other alternatives that might not need G-CSF but you could maintain the same outcomes. Brittany Harvey: Understood. It's helpful to review those options for clinicians and showing that there's not just one way to address potential neutropenic complications for later cycles of chemotherapy. So then following those recommendations for prophylaxis, what does the expert panel recommend regarding CSFs for the treatment of febrile neutropenia? Dr. Bishal Gyawali: This is an important question because this ties strongly with the "Choosing Wisely" campaign. In other words, primary and secondary prophylaxis we talked about when CSF should be used; here we make a sort of negative recommendation in that we say when CSF should not be used, because this is where we see most overuse or overtreatment with G-CSF. So first, we say that we should not be using a CSF routinely simply because a patient has neutropenia. If they are afebrile but they only have neutropenia, we recommend against using CSF just to boost neutrophil counts; that's not a meaningful metric. Then the second recommendation we make is CSF should not be routinely used as an adjunctive treatment with antibiotic therapy for patients with fever and neutropenia. So the first one was neutropenia, no fever, don't use it. The second one is okay, there is neutropenia and fever, but the treatment for that is use of antibiotic therapy, and so in such situations routinely we should not be using G-CSF just to boost the neutrophil count. And that is tied on to the third recommendation where if the patient has fever and neutropenia but is also at a very high risk for infection-related complications or who have other prognostic factors that we think will lead to poor outcomes for the patient, then in such situations, a CSF can be used as an adjunctive treatment. But we talk about the data in the manuscript, but the data show that the most that this will do is reduce the days of hospitalization by a couple of days. It actually does not have any data that it's going to improve the mortality rates. So as of now, we use the word "may be offered," it's not "should be offered," it's "may be offered" if there are other factors that we think will make the patient at the very poor risk of mortality outcomes, and the evidence quality here therefore is low and our strength of recommendation is conditional. And we also have a box that lists those items that we think might be associated with poor prognosis for the patients, but again the data for those, are they really hard evidence? No. And that is also tied with our future research recommendation that we should study more about these factors that might lead to these poor outcomes. Dr. Tessa Cigler: And again, allowing for discretion of the treating physician. Brittany Harvey: Absolutely. It's just as important to know when not to use CSFs routinely, and those risk factor boxes that you mentioned are available in the full manuscript along with the full list of recommendations, and our listeners can refer to that; a link will be in the show notes of the episode . Dr. Tessa Cigler: Just so you know, the panel, we really discussed those criteria a lot and agonized over them and gave you our best recommendations. Brittany Harvey: Definitely, and it sounds like there was varying degrees of evidence to support a lot of those risk factors, and so it's really important that the evidence supports those, but also there was expert consensus of the panel in reviewing each of those factors individually to come up with recommendations that can be applicable for all clinicians. Dr. Bishal Gyawali: If I may add, we're proud of our panel because I think our panel is quite inclusive of people representing different specialties within cancer care, as in we had radiation oncologist, we had infectious disease expert, pharmacists, and most importantly, we also had patient partners. Brittany Harvey: Absolutely. Having a multidisciplinary panel is really important for each and every guideline. So then, this is probably relevant now, but addressing a few more specific sections addressed in the guideline, what is the role of CSFs as adjuncts to progenitor cell transplantation? Dr. Tessa Sigler: Great question, and so, as solid tumor oncologists, Dr. Gyawali and I really leaned heavily on our hematology experts within the panel. The panel decided that a CSF should be used alone after chemotherapy or in combination with a CXCR4 inhibitor to mobilize peripheral blood progenitor cells. Clearly the choice of mobilization strategy depends on the type of cancer and the type of transplantation. The panel noted that a CSF should be routinely administered after autologous stem cell transplantation to reduce the risk of severe neutropenia, and that a CSF may be administered after allogeneic stem cell transplant to reduce the duration of severe neutropenia. Again, this last recommendation has not a lot of evidence to support it, and so we kind of tempered our language that it may be administered or can be considered based on clinical judgment of the physician and the clinical status of the patient. Brittany Harvey: And that really highlights the need for a multidisciplinary panel, because as you are solid tumor oncologists, you need the hematologists to make recommendations for all sorts of patients and make sure that these guidelines are comprehensive.   So then moving on to another smaller subset population, for patients receiving concomitant chemotherapy and radiation therapy, are CSFs recommended? Dr. Bishal Gyawali: I think there is very little evidence for patients who are receiving radiation therapy alone, so there is no evidence to suggest the use of CSF in patients with radiation therapy alone. The bigger question is in patients who are receiving both chemo and radiation together, chemoradiotherapy. In those patients, up until now, the classical recommendation has been to avoid G-CSF use. I think in our updated guidelines we discuss a couple newer trials that are trying to address this issue, but in the totality of evidence, we still stick with the same recommendation as before, which is CSFs are not recommended in patients receiving concomitant chemotherapy and radiation therapy, especially those involving the mediastinum because the biggest evidence of harm is for these patients. Dr. Tessa Cigler: I agree completely. Brittany Harvey: Definitely. It's important to recognize when that balance of benefits and harms leans more towards harms, and so that this should not be recommended for those patients. So there are several different CSFs that are recommended in the guideline, including biosimilars. So do the recommended CSFs differ in efficacy or safety? Dr. Tessa Cigler: So as supported by evidence, and the panel all agreed, that the various forms of CSFs, including the biosimilars, really have the same evidence for efficacy and for safety, and that the choice of agent really should depend on cost, availability, accessibility, patient convenience, and sometimes disease subtypes and treatment regimens. But, in essence, these can be used interchangeably without concern for efficacy or toxicity differences. Dr. Bishal Gyawali: I completely agree. I think in terms of efficacy outcomes, I don't think there is anything to choose between these agents. The choice between these agents would largely depend on different patient and treatment-related factors: cost, availability, affordability, feasibility. We even discuss things like where does the patient live, as in how frequently the patient can commit to the cancer center, and we also discussed things like even for the daily shots of filgrastim, patients can be taught and they can get it by themselves at home. So we discussed all these factors, but in a nutshell, the choice within these agents primarily depends not on efficacy factors, but simply based on all these other factors that are equally important but which can lead to informed decision-making about what is best for a given patient. But we mention it explicitly that the biosimilars, there is nothing to choose between them, especially the biosimilars; it's about price competition and what you can get at an affordable rate. Brittany Harvey: Understood. It's great to have many different options for patients so that there's something that can work for them based off access, cost, and all these factors that you listed. As you mentioned, it may be easier for some patients to get their treatment at home rather than in clinic, and so having different options and reviewing those with patients is very important. Dr. Bishal Gyawali: As we are having this conversation, I'm thinking that we might be a very unique guideline in that I don't think in many other settings you have this many options that you are asking about, you know, choices between equally good options and making decisions based on cost. I don't think there are any other areas in oncology where we have the privilege of making these decisions based on cost and convenience and all these factors, as well as we might be one of those guidelines where we have, as discussed before, so many recommendations about when not to do things and trying to promote judicial use of treatments. Dr. Tessa Cigler: As you might imagine, our panel discussions were very lively. Dr. Bishal Gyawali: Yes. But Dr. Cigler, do you recall any other guideline where there is so much discussion about when not to use things and how we have so many biosimilar options and we can choose the one that's most appropriate? I don't recall any other. Dr. Tessa Cigler: I agree with you. Brittany Harvey: It's certainly a unique guideline in that regard. So we'll move into the last clinical question that the expert panel addressed. But what does the expert panel recommend for the initiation, duration, dosing, and administration of CSFs? Dr. Bishal Gyawali: Yeah, I think there has been some new data in this regard that were not available in the previous guideline. For example, we have new trials testing a shorter duration of filgrastim injections compared to the standard of care. So we have some data, we call this 'de-escalation of treatment'. So we have more data supporting de-escalation of treatment. We have some data for lower dose of pegfilgrastim, we have data for lower duration of filgrastim, we have also some new data about timing of treatment, as in there has been some newer data presented about the relationship of timing of the drug and the frequency of adverse events from G-CSF such as bone pain. There is also the question about, for patients who don't live near the cancer center, can they get their pegfilgrastim shot on the day of chemo while they are in the cancer center? So all these questions that are very pragmatic and important questions, but were not answered before, we're glad that we had more evidence to talk about all these factors and give a more solid recommendation to our users of the guideline. Brittany Harvey: Definitely. And listeners can review the full list of dosing and administration recommendations in Table 2 in the guideline, and that will be linked in the show notes of the episode. So then I really want to thank you both for reviewing all of these recommendations. There's certainly a large amount of clinical questions and recommendations that you went through. I'd like to next ask, in your view, what is the importance of this updated guideline and how will it impact both clinicians and patients? Dr. Bishal Gyawali: I think the importance of this updated guideline is that, as mentioned before, we talk about newer data that have come up with regards to not just the most important two questions as in when to use it as primary prophylaxis and when to use it as secondary prophylaxis and when to use it as treatment, but also with regards to the duration and timing and dosing and multiple options and how these all factors as well as patient-related factors should be combined to make an informed decision, the most appropriate decision for the patient. And as mentioned before, we have the GRADE tables that were not in the previous version of this guideline. So I think even those users that are familiar with the 2015 guideline, I think they will find very novel content in this new updated guideline, and they will find it useful for their practice. I would encourage the readers to not only read the headlines of the box recommendations, but also read the full text of these guidelines because we have worked really hard to incorporate the latest evidence and also interpret them contextually. The discussion regarding de-escalation, patient considerations, cost implications; usually, people just skip these portions when they read a guideline. But I think these are also one of the most important paragraphs in our guideline, so they have been written with very careful thought, and I think reading the whole guideline is very much worth your time. Dr. Tessa Cigler: As you can imagine, I agree completely, having just spent several months thinking about these guidelines and all their nuances. Brittany Harvey: Certainly, this guideline is definitely a very comprehensive update, and that nuance in the manuscript is really important for clinicians to understand and read through and understand when it's appropriate to make certain decisions. So then to wrap us up, I'd like to ask, what are the outstanding questions and active research areas regarding the use of white blood cell growth factors in patients with cancer? Dr. Tessa Cigler: As you all know from clinical practice and that we've said several times already in this podcast is that the risk factors for the development of complications of febrile neutropenia are still not clearly worked out. And one of the things that is, I think, really needed in clinical practice is the development of predictive algorithms or biomarkers to really allow us to understand who might be more at risk and to allow for the clinician to be able to tailor the use of G-CSF as needed. Brittany Harvey: Yes, and so we'll look forward to future updates in this space to inform new recommendations and an updated guideline in the future. So I want to thank you both so much for your work to develop this comprehensive guideline. It was certainly a lot of effort, and thank you for your time today, Dr. Gyawali and Dr. Cigler. Dr. Tessa Cigler: Oh, my pleasure. It's nice to be here and to speak with you all. Dr. Bishal Gyawali: Yeah, it was great to speak with both of you but also through you to the audience, and we had a great time. Thank you. Brittany Harvey: And then finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/supportive-care-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app, available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

The TKI Crew are back asking the age old question, "Do you have to go a Division 1 school as a goalkeeper to play at the next level? The gang breaks down all the pluses and minuses of focusing solely on D1 opps and why environment matters more than level. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In‑car technology continues to evolve as drivers seek faster, simpler, and more seamless ways to connect their smartphones to their vehicles. Ottocast focuses on wireless CarPlay and Android Auto solutions designed to eliminate the need for cables and reduce the friction that often accompanies daily driving routines. The company develops compact plug‑and‑play devices that convert wired CarPlay systems into wireless experiences, supporting a more convenient and efficient workflow for drivers who rely on navigation, communication, and media throughout the day.The shift toward wireless connectivity reflects a broader trend in automotive technology, where drivers expect their vehicles to integrate smoothly with their digital lives. Many factory‑installed systems still require a physical cable to activate CarPlay or Android Auto, creating inconvenience for users who frequently enter and exit their vehicles. Ottocast addresses this gap by offering a device that plugs directly into the vehicle's USB port and establishes a wireless bridge between the car and the smartphone. Once paired, the system reconnects automatically each time the vehicle starts, eliminating repeated setup steps.Plug‑and‑Play Wireless ConnectivityThe wireless adapter developed by Ottocast uses Bluetooth for initial pairing and Wi‑Fi for ongoing data transmission, enabling low‑latency performance suitable for navigation, calls, and media playback. The device is designed to function as a transparent intermediary, allowing the vehicle to recognize the smartphone as if it were physically connected. This approach supports compatibility across a wide range of vehicles and mobile devices, making the solution accessible to drivers who want wireless functionality without upgrading their entire infotainment system.The convenience of wireless CarPlay and Android Auto is particularly valuable for drivers who rely on frequent stops, such as rideshare and delivery professionals. The ability to enter and exit the vehicle without repeatedly plugging and unplugging a cable reduces wear on ports, saves time, and supports a smoother workflow. The system also benefits everyday drivers who prefer a cleaner cabin environment without visible cables.Expanding the Platform with In‑Car Android SystemsBeyond wireless adapters, Ottocast has developed standalone in‑car Android systems that function as compact computing platforms. These devices plug into the vehicle and provide access to applications from the Google Play Store, enabling navigation, entertainment, and productivity tools directly through the vehicle's display. This approach transforms the infotainment system into a flexible, app‑driven environment that can be customized to the driver's needs.One of the company's recent additions includes a rear‑seat or rear‑facing camera designed to support families with infants or young children. The camera integrates with the in‑car display through picture‑in‑picture or split‑screen modes, allowing drivers to monitor a child safely without turning around. This feature reflects a growing emphasis on safety‑enhancing technologies that reduce distraction while maintaining situational awareness.Global Availability and User‑Focused DesignOttocast's products are available through the company's website and major online retailers, supporting global access to wireless connectivity solutions. The devices are designed for ease of use, requiring no technical expertise or installation services. The company conducts extensive compatibility testing across thousands of vehicle models to ensure reliable performance in diverse markets.The focus on convenience, safety, and user experience positions Ottocast as a contributor to the broader evolution of in‑car technology. As drivers continue to expect seamless integration between their vehicles and their digital ecosystems, solutions that simplify connectivity will remain essential.ConclusionOttocast advances in‑car connectivity through wireless CarPlay and Android Auto adapters, standalone Android systems, and safety‑enhancing camera integrations. By eliminating cables, simplifying setup, and expanding access to app‑driven experiences, the company supports a more convenient and modern driving environment. As automotive technology continues to evolve, wireless solutions like these play a key role in shaping the future of digital mobility.Ottocast devices are available today on Amazon and Ottocast's website.Interview by Scott Ertz of F5 Live: Refreshing Technology.Sponsored by: Get $5 to protect your credit card information online with Privacy. Amazon Prime gives you more than just free shipping. Get free music, TV shows, movies, videogames and more. Secure your connection and unlock a faster, safer internet by signing up for PureVPN today.

In‑car technology continues to evolve as drivers seek faster, simpler, and more seamless ways to connect their smartphones to their vehicles. Ottocast focuses on wireless CarPlay and Android Auto solutions designed to eliminate the need for cables and reduce the friction that often accompanies daily driving routines. The company develops compact plug‑and‑play devices that convert wired CarPlay systems into wireless experiences, supporting a more convenient and efficient workflow for drivers who rely on navigation, communication, and media throughout the day.The shift toward wireless connectivity reflects a broader trend in automotive technology, where drivers expect their vehicles to integrate smoothly with their digital lives. Many factory‑installed systems still require a physical cable to activate CarPlay or Android Auto, creating inconvenience for users who frequently enter and exit their vehicles. Ottocast addresses this gap by offering a device that plugs directly into the vehicle's USB port and establishes a wireless bridge between the car and the smartphone. Once paired, the system reconnects automatically each time the vehicle starts, eliminating repeated setup steps.Plug‑and‑Play Wireless ConnectivityThe wireless adapter developed by Ottocast uses Bluetooth for initial pairing and Wi‑Fi for ongoing data transmission, enabling low‑latency performance suitable for navigation, calls, and media playback. The device is designed to function as a transparent intermediary, allowing the vehicle to recognize the smartphone as if it were physically connected. This approach supports compatibility across a wide range of vehicles and mobile devices, making the solution accessible to drivers who want wireless functionality without upgrading their entire infotainment system.The convenience of wireless CarPlay and Android Auto is particularly valuable for drivers who rely on frequent stops, such as rideshare and delivery professionals. The ability to enter and exit the vehicle without repeatedly plugging and unplugging a cable reduces wear on ports, saves time, and supports a smoother workflow. The system also benefits everyday drivers who prefer a cleaner cabin environment without visible cables.Expanding the Platform with In‑Car Android SystemsBeyond wireless adapters, Ottocast has developed standalone in‑car Android systems that function as compact computing platforms. These devices plug into the vehicle and provide access to applications from the Google Play Store, enabling navigation, entertainment, and productivity tools directly through the vehicle's display. This approach transforms the infotainment system into a flexible, app‑driven environment that can be customized to the driver's needs.One of the company's recent additions includes a rear‑seat or rear‑facing camera designed to support families with infants or young children. The camera integrates with the in‑car display through picture‑in‑picture or split‑screen modes, allowing drivers to monitor a child safely without turning around. This feature reflects a growing emphasis on safety‑enhancing technologies that reduce distraction while maintaining situational awareness.Global Availability and User‑Focused DesignOttocast's products are available through the company's website and major online retailers, supporting global access to wireless connectivity solutions. The devices are designed for ease of use, requiring no technical expertise or installation services. The company conducts extensive compatibility testing across thousands of vehicle models to ensure reliable performance in diverse markets.The focus on convenience, safety, and user experience positions Ottocast as a contributor to the broader evolution of in‑car technology. As drivers continue to expect seamless integration between their vehicles and their digital ecosystems, solutions that simplify connectivity will remain essential.ConclusionOttocast advances in‑car connectivity through wireless CarPlay and Android Auto adapters, standalone Android systems, and safety‑enhancing camera integrations. By eliminating cables, simplifying setup, and expanding access to app‑driven experiences, the company supports a more convenient and modern driving environment. As automotive technology continues to evolve, wireless solutions like these play a key role in shaping the future of digital mobility.Ottocast devices are available today on Amazon and Ottocast's website.Interview by Scott Ertz of F5 Live: Refreshing Technology.Sponsored by: Get $5 to protect your credit card information online with Privacy. Amazon Prime gives you more than just free shipping. Get free music, TV shows, movies, videogames and more. Secure your connection and unlock a faster, safer internet by signing up for PureVPN today.

With the midweek win done and dusted, we can finally focus on the meat and potatoes of the MLS regular season! Just two months away from competition feels like a hunger strike, especially after watching That Team From Florida enjoy all the fine dining last December. FC Cincinnati heads into Season 5 under Pat Noonan with some big statements to make, but let's not forget that this weekend's opponent experienced bigger disappointment after promises of gold. Atlanta United brought the band back together by rehiring their best conductor, Tata Martino, to helm the sidelines. What can we expect out of the "5 Stripes" with a similar roster and a more familiar head coach? We've brought in an old friend to the show, Tyler Pilgrim from Scarves & Spikes, to set the table for Saturday. Can Atlanta bring back the golden days of the 2010s and get back on the medal stand again? What will the Starting XI look like under Martino's guidance? Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

This week, we're revisiting an episode where Marianna sat down with John Faragon to talk about post-exposure prophylaxis in pocket or PIP. Listen in to learn all about what it is, who it's for, and how it can help prevent HIV for more people.-- Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

In Episode 56 Landon urges us to slow down a bit, to relax. One of the ways in which we accomplish this is to Embrace Life's Undeniables. This is the 4th Key to living fully...excerpted from "The Significant Seven", a 7-part addition to the Heartbeat App. You can get the entire course, including thought provoking insights from Landon and an accompanying exploration workbook, now included in the Heartbeat App. The App is free, and can be downloaded from the Apple App Store or the Google Play Store.

The TKI Crew keeps it rolling with a "Brave" Pod :P. That's right, today's topic is what it means to be a brave goalkeeper. The crew breaks it down from a micro and macro standpoint.  Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

I18 GK Podcast is back this month w/ Sac Republic's Kris Hall! The crew chat overseas badges, the upcoming USSF course, and how to balance your independent academy w/ your Pro Club's commitments. Great listen for young coaches, players and parents!! Download the Union GK community on Apple or Google Play Stores for more! Video Link Here - https://www.theunionsports.com/feeds/2491611 *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union! Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises for players to fine-tune technical and tactical awareness. Pro Analysis Tools: Receive insightful feedback on past performance from expert coaches to elevate your game. Mindset and Performance Coaches: Access to coaches specializing in mental toughness in soccer players. Access to help to boost self-esteem, conflict resolution with coaches and players, and mindset. The Gift That Keeps Them in the Game! Your Premium Subscription to The Union Goalkeeper App offers easily accessible tools at the low yearly cost of $49.99 - Subscribe now for the year, and you'll receive an exclusive UNION GK premium hat (retail value $25.00)! Use code HOLIDAYGWP at checkout. Don't miss out – Keeperstop Coupon Code: Union GK members can save an additional 10% with code: UGK23. Contact the goalkeeper equipment experts in the USA for goalkeeper gloves and equipment. Always always available to answer any sizing or equipment question. Don't forget to sign up for office Hours on the Union GK App Portal https://www.theunionsports.com/office_schedulers?k=c1a46a8b Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Want to increase your organic downloads without spending money on ads? In this video, I break down our proven app store optimization (ASO) framework for 2026. Whether you are an indie developer or managing a big brand, these strategies will help you rank higher on both the Apple App Store and Google Play Store.We cover the exact steps we use at App Masters to help clients find success, from keyword research to conversion rate optimization.In this ASO tutorial, you will learn:✅ The most important ASO ranking factors in 2026✅ How to find low-competition keywords that still drive revenue✅ The do's and dont's of selecting keywords✅ Some Real Case Studies:- $1,600 in revenue in the first 22 days from organic search- $3,000/month purely from long-tail ASO strategy- 90+ #1 keyword rankings using low-traffic terms

It's that time of year again as the Geek Salad crew waxes nostalgic about the music from 30 years ago. In this installment, they discuss their favorite album releases of the year 1996! Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Blue Sky feed: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.  

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

At ITEXPO / MSP EXPO in Fort Lauderdale, Doug Green, Publisher of Technology Reseller News, spoke with Jon Brinton, Chief Revenue Officer at Crexendo, about the company's latest announcement: the launch of the Crexendo Marketplace. Crexendo is also a member of the Cloud Communications Alliance (CCA). Crexendo, a unified communications service provider, merged with NetSapiens five years ago, bringing together a robust UCaaS platform now powering approximately 240 service providers globally. That ecosystem supports nearly 7.5 million users—a number that has grown more than fourfold since the acquisition. The new Crexendo Marketplace builds on that momentum by delivering a centralized, frictionless application store for certified integrations and third-party solutions. “What we've now released is a Crexendo Marketplace,” Brinton explained. “If you think about it like the Google Play Store or the Apple Store, it's an application store that somebody can go to download, activate or integrate with applications that are certified for our platform.” Through one-touch provisioning, service providers can enable integrations such as mobile dialer support, analytics, Microsoft Teams connectivity, and Crexendo's AI-powered receptionist and orchestrator, Cairo—all without complex implementation paths. The Marketplace reinforces Crexendo's sessions-not-seats licensing model, which allows MSPs and service providers to own their customer relationships while building equity in their businesses. Brinton noted that AI-driven add-on applications are driving significant incremental revenue, often far exceeding traditional per-user UCaaS pricing. “Some of these AI applications… may be worth four to five to ten times that in monthly revenue to our partners,” he said, underscoring the opportunity for higher-margin growth. As innovation accelerates across the cloud communications landscape, Crexendo continues to invest heavily in platform development and ecosystem expansion. With its annual NetSapiens user group meeting scheduled for Austin later this year, the company remains focused on empowering partners with tools, integrations, and community support to compete—and win—in an evolving market. Visit https://www.crexendo.com/

One week until meaningful soccer and the launch of a promising FC Cincinnati season! We enter Year 11 the same way as last season, with the Orange & Blue leaving the country for CONCACAF Champions Cup coverage. Soon enough, the MLS season also starts with designated players Evander, Miles Robinson, and Kevin Denkey leading a talented roster. But what are we really looking at? How promising and hopeful are we that this roster can use consistency and build from last season's hard work? We ask the FC Cincinnati radio broadcast team, Tommy G. and Kevin McCloskey, what they think about this roster and the long road ahead. (And perhaps a bit about the big tournament this summer!) Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

The TKI Crew returns for Winter 2026! On Today's episode, Jill ,Tori and Kira discuss how college goalkeepers can transition into coaching. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

It's that time of year again as the Geek Salad crew waxes nostalgic about the music from 30 years ago. In this installment, they discuss the singles of the year 1996! And stay tuned for Side 2: The Albums next week! Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Blue Sky feed: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.  

Thank you for joining us! To stay connected with us visit us here, on SoundCloud and on: Website: https://www.mynpmc.com/ Facebook: https://www.facebook.com/mynpmc YouTube: https://www.youtube.com/channel/UCnOiemCev_mHyZNgU2QgwnA Download the NPMC app on the: Google Play Store: https://play.google.com/store/apps/details?id=com.echurchapps.newparis&hl=en_US Apple App Store: https://apps.apple.com/us/app/new-paris-missionary-church/id1228753320 Give Online: https://pushpay.com/g/newparismissionarychurch New Paris Missionary Church is located in New Paris, Indiana. We would love for you to join us in person or online on Sundays as we worship God together. Our service begins at 10:00 a.m. We hope to see you soon!

FC Cincinnati has officially played ten years of soccer for the Queen City. Fans have experienced a decade of the highest highs and lowest lows, and we here at Cincinnati Soccer Talk have been there every minute along the way. We've held wooden spoons and supporter shields with the fans. We've held the microphones in front of the players and coaches. Ever since the hosts met for their first podcast in February of 2016, CST has worked to paint the picture of Cincinnati as a soccer city. (In some cases, that paint involved actual body paint!) To open the year's first Jersey Swap podcast, we've brought in some of our alumni—Nick Seuberling, Bryan Weigel, and Bill Wolf—to talk about CST's origins and best moments. Additionally, we ask them about how confident we feel about the 2026 season. And maybe we wrap things up with a quiz to see how well the triad remember that first season! Tune in and trade threads with us! #MLS #FCCincinnati #soccer Become a Patron! Subscribe to Cincinnati Soccer Talk Don't forget you can now download and subscribe to Cincinnati Soccer Talk on iTunes today! The podcast can also be found on Stitcher Smart Radio now. We're also available in the Google Play Store and NOW ON SPOTIFY! As always we'd love your feedback about our podcast! You can email the show at feedback@cincinnatisoccertalk.com. We'd love for you to join us on our Facebook page as well! Like us at Facebook.com/CincinnatiSoccerTalk.

Every other week I'm republishing one of my most popular or impactful episodes from my backlog of over 450 episodes. This week I'm highlighting Episode 410, which is all about post-op pediatric airway emergencies.  You don't want to miss this one! ___________________ ⁠Full Transcript⁠ - Read the article and view references ⁠Episode 140⁠ - Listen to episode 140 for an overview of pediatric respiratory distress. ⁠FREE CLASS⁠ - If all you've heard are nursing school horror stories, then you need this class! Join me in this on-demand session where I dispel all those nursing school myths and show you that YES...you can thrive in nursing school without it taking over your life! ⁠Study Sesh⁠ - Change the way you study with this private podcast that includes dynamic audio formats including podquizzes, case studies and drills that help you review and test your recall of important nursing concepts on-the-go. Free yourself from your desk with Study Sesh!  ⁠Straight A Nursing App⁠ - Study on-the-go with the Straight A Nursing app! Review more than 5,000 flashcards covering a wide range of subjects including Fundamentals, Pediatrics, Med Surg, Mental Health, Maternal Newborn, and more! Available for free in the Apple App Store and Google Play Store. NCLEX Study Plan - Not sure how to plan your NCLEX studying or which topics to focus on? Grab this free guide which details strategies based on how much time you have to prepare.

This week, Marianna sits down with Chris Bositis and Cara McAnaney from the National Clinician Consultation Center (NCCC) to talk all about lower-barrier substance use and HIV prevention and treatment. Tune in to learn how direct-to-inject ties into that and why it matters for you as an HIV care provider. -- Resources: Waters RC, Hoog J, Bell C, Toland P, Valley J, Hurtado L, Kallsen MA, Johnson T, Gerard A, Fockele CE, Klein JW. Injectable-Only Overlapping Buprenorphine Starting Protocol in a Low-Threshold Setting. JAMA Netw Open. 2025 Aug 1;8(8):e2527016. doi: 10.1001/jamanetworkopen.2025.27016. PMID: 40815514; PMCID: PMC12357186.Rosenwohl-Mack S, Suen LW, Logan AA, Peterson D, Snyder HR. Outpatient Initiation of 7-Day Injectable Buprenorphine: A Direct-to-Inject Case Series. Subst Use Addctn J. 2025 Oct;46(4):1064-1069. doi: 10.1177/29767342251330412. Epub 2025 Apr 4. PMID: 40183345; PMCID: PMC12353995.D'Onofrio G, Herring AA, Perrone J, Hawk K, Samuels EA, Cowan E, Anderson E, McCormack R, Huntley K, Owens P, Martel S, Schactman M, Lofwall MR, Walsh SL, Dziura J, Fiellin DA. Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal. JAMA Netw Open. 2024 Jul 1;7(7):e2420702. doi: 10.1001/jamanetworkopen.2024.20702. PMID: 38976265; PMCID: PMC11231806. Help us track the number of listeners our episode gets by filling out this brief form! (https://www.e2NECA.org/?r=AQX7941)--Want to chat? Email us at podcast@necaaetc.org with comments or ideas for new episodes. --Check out our free online courses: www.necaaetc.org/rise-courses--Download our HIV mobile apps:Google Play Store: https://play.google.com/store/apps/developer?id=John+Faragon&hl=en_US&gl=USApple App Store: https://apps.apple.com/us/developer/virologyed-consultants-llc/id1216837691

The TKI Crew returns for Winter 2026! On Today's episode, Jill & Tori are joined by a special guest (possibly a new cast member? :P ) Kira Ketelhut to discuss what are 3 main takeaways from offseason Pro GK training week that young goalkeepers can learn from. Great listen for young coaches, players and parents! Share your feedback! Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 And if you want to make sure you never miss an episode of any of our other fantastic  shows such as Gloves off w/ Saskia Webber & Inside the 18 w/ Michael Magid, all  you have to do is subscribe to the union gk app. For more info go to www.theuniongk.com or Download the Union GK Community, on apple or google play stores. Thanks for making The Union Possible & on with the show! *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular TKI Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Dr. Joshua Reuss is back on the podcast to discuss the full update to the living guideline on stage IV NSCLC without driver alterations. He discusses the new evidence and how this impacts the latest recommendations on first-line and subsequent therapeutic options. Dr. Reuss emphasizes the need for shared decision-making between clinicians and patients. He shares ongoing research that the panel will review in the future for further updates to this living guideline, and puts the updated recommendations into context for clinicians treating patients with stage IV NSCLC. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines" TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02825    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I am interviewing Dr. Joshua Reuss from Georgetown University, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It is great to have you back on the show today, Dr. Reuss. Dr. Joshua Reuss: Happy to be here, Brittany. Brittany Harvey: Just before we discuss this guideline, I would like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Reuss who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. Dr. Reuss, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer without driver alterations is updated on an ongoing basis. So, what prompted this latest update to the recommendations? Dr. Joshua Reuss: Our committee is tasked with making routine updates to the living guidelines and really keeping them living, right? So, evaluating new data as it is coming in to see, is this practice changing? Is this data that should inform and potentially alter our guideline recommendations so that practitioners and other care providers could really make the best treatment decisions for their patients? So that is something that happens on a more routine basis, but periodically, we are tasked with performing a more comprehensive update of our guideline where we really evaluate every one of our point recommendations, the data associated with these recommendations, to be sure that these are up to date, these are comprehensive, and to see if we need to alter anything in the language of these updates. Brittany Harvey: Excellent. Thank you for providing that background. And yes, this is truly a comprehensive update that goes through all the latest literature. Given that, I would like to review what has changed and what is new in the recommendations. So, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: So there are two main guidelines that we recommend from this panel. One is a driver mutation-positive guideline and the other is a driver mutation-negative guideline. And I think on first blush, one might look at kind of the recent flurry of approvals and new data and say, well, all the excitement, you know, is in the driver mutation-positive guideline. But I would say that the driver mutation-negative guideline is equally as important and really has several unique challenges associated with it. You know, first and foremost is that there are really a multitude of regimens that can be considered for any one patient. And how to choose between one can be quite difficult and a stressful challenge that clinicians can have, particularly since there are really no randomized studies comparing these regimens in a head-to-head fashion. In addition, you know, these guidelines are really broken down by two key factors. One is disease histology, so namely squamous versus non-squamous histology. And the other is PD-L1 status, broken down into one of three tertiles: PD-L1 high, which is greater than or equal to 50% expression; PD-L1 low, which is 1% to 49% expression; and then PD-L1 negative or unknown. So what you are really looking at, if you do that math, is really six unique patient subpopulations where we need to make a recommendation on one of the multitude of treatment regimens that is approved. And what that means is you are oftentimes really looking at subset and sub-subset level data to help inform clinicians in their treatment decision making, which can be quite challenging because as those small subsets of data is more and more parsed, there are many confounders that can be interjected there. And so I think the committee is tasked with really quite a challenge in terms of how to really communicate and broadcast that data in a way that informs clinicians in making a decision on what is the right treatment for their patient. Brittany Harvey: Absolutely. It can be challenging to interpret that subgroup data across several different studies that are reporting on different regimens and different outcomes. And I appreciate you mentioning the driver mutation-positive guideline as well. Listeners can check out the companion episode with Dr. Puri for more information on what is changed in the driver mutation-positive guideline. Based on that primer, what is new for first-line therapy for patients with stage IV non-small cell lung cancer without driver alterations? Dr. Joshua Reuss: Even though I will say there is not a lot of new trial data that was incorporated into this guideline, there were some updates and just some meaningful long-term data that we incorporated. I think first and foremost, there is a new top-level recommendation in this guideline pertaining to molecular testing, which is absolutely critical in both the driver mutation-positive and driver mutation-negative space. I think we tend to think that, oh, well, molecular testing really only pertains to then finding a driver mutation. But the lack of a mutation is absolutely critical as well, right? Because that is what leads us down the mutation-negative pathway. We also need this molecular testing to assess PD-L1 status. We are seeing emerging data on molecular mutations that might confer resistance to certain immunotherapy-based strategies. So the committee felt strongly that a recommendation on molecular testing is critical to include in both the driver mutation-positive guideline and the driver mutation-negative guideline. I will also say that we are now seeing five and six-year updates from some of the landmark trials of immunotherapy in driver mutation-negative non-small cell lung cancer. It is really incredible to see that in some of these trials, we are seeing very impressive durability of the treatment in the patient subsets that we are commenting on. In others, perhaps that durability is less clear, and I think that leads to challenges in making a recommendation on any one particular regimen. And I think that is nowhere more clear than in the squamous subset. I think that was one perhaps subtle change that is in this guideline where, particularly in the PD-L1 negative squamous population, the committee felt that no one regimen really was worthy of standing above the others. Sometimes I think it is important to really champion one unique regimen if we feel that the data is there to support it. But I think it is equally important to list multiple regimens where the data is less clear. I think another point is that while perhaps there were no new regimens that we have added or that led to other clear changes in the prioritization of one regimen over another, there are other unique data subsets that I think come into play in making a decision and that really are important when looking at the discussion on any one recommendation from this guideline. For example, we know there is emerging data on perhaps the significance of molecular alterations in KEAP1 or STK11 and how that might influence frontline decision-making. You know, there is not a prospective phase III trial in this population, but I think we still need to use that data in certain scenarios to make recommendations for a particular patient. Another example of a trial that, again, did not change our recommendations, but I think one can incorporate in their decision making is the KEYNOTE-598 trial. Now, this is not a new study, but what it studied was pembrolizumab versus pembrolizumab plus ipilimumab in a PD-L1 high subset, and found that the addition of ipilimumab to pembrolizumab in the PD-L1 high population did not significantly improve clinical efficacy. And so while pembrolizumab plus ipilimumab is not an approved regimen, it is hard to extrapolate that to our combination treatments that are approved. I think some clinicians might find that data valuable when making a frontline treatment decision on a patient who has PD-L1 high status. So a bit of a whirlwind tour, but I think there are still multiple factors that went into this guideline that are important to review when making treatment decisions for any one patient. Brittany Harvey: Absolutely. I think what you just mentioned in having that upfront molecular testing is really key for individualized patient care. And the evidence summaries that you provide in addition to the recommendations are really important for clinicians to be able to refer to as they are making decisions in their clinic. So then beyond those changes for first-line therapy, what is updated for second-line and subsequent therapies? Dr. Joshua Reuss: For second-line and subsequent therapies, we did see one new treatment recommendation join these ranks, and that was telisotuzumab vedotin. Telisotuzumab vedotin, quite a mouthful. That is an antibody-drug conjugate. I like to think of that as smart chemotherapy, targeted chemotherapy, where you are trying to utilize some aspect of a marker that is selectively expressed or overexpressed on the cancer surface to then shepherd in the anticancer molecule, a highly potent chemotherapeutic in the case of currently approved antibody-drug conjugates, to exert antitumor killing effect. So in this case, the antibody-drug conjugate telisotuzumab vedotin targets MET overexpression. So telisotuzumab is an antibody targeting MET, and that is conjugated to an MMAE highly potent chemotherapeutic payload called vedotin. So we know MET can be selectively expressed and overexpressed in non-small cell lung cancer in both driver mutation-positive and mutation-negative subsets. The data that led to this approval was from the phase II LUMINOSITY trial which evaluated telisotuzumab vedotin, or Teliso-V, in many subsets. But the subset that really showed promise and was expanded was the EGFR wild-type, non-squamous, non-small cell lung cancer population with MET overexpression. And so in 78 patients with high levels of expression, the response rate here was 34.6%, median progression-free survival of 5.5 months, and a median overall survival of 14.6 months. With an overall acceptable safety profile; grade 3 or higher adverse events, neuropathy was perhaps the most common at 7%, also increased ALT at 3.5%, and pneumonitis at 2.9%. Now this was phase II data that led to an accelerated approval. There is an ongoing phase III study randomizing patients with high expression to Teliso-V versus docetaxel. That is the phase III TeliMET study. But it is nice that we now have another option for patients, perhaps a more biomarker-directed option with, again, this MET overexpression. And again, it further reinforces the importance of molecular testing in patients with traditionally driver mutation-negative non-small cell lung cancer, whether that is upfront or at progression, and in particular utilizing immunohistochemistry to assess MET expression in these patients. And this does join another ADC that we had previously made an update in our recommendation, which is trastuzumab deruxtecan, which is approved for those patients with HER2-overexpressing non-small cell lung cancer. So just again to reiterate the importance of molecular testing in patients both at the outset of their treatment and upon progression on frontline therapy. Brittany Harvey: Definitely. It is great to have this new antibody-drug conjugate join the treatment options, and as you mentioned, very important in this case to have that molecular testing done at the outset and at progression. So then in your view, what should clinicians know as they implement this living guideline, and how do these changes impact patients with non-small cell lung cancer? Dr. Joshua Reuss: Because there are so many different regimens that one can consider for any one patient, I think it is easy to become overwhelmed and stress on, "Am I making the right choice for my patient?" And I think one of the key take home points is that in many cases, there is no one right regimen. And I think one has to weigh several factors. It is the treatment schedule. It is the toxicity profile. It is the molecular profile of the patient. It is the patient preference. You know, there are so many factors here. And I would like to draw the reader and viewer's attention to an important section of these guidelines, particularly the Patient and Clinician Communication section, where we have a box focused on discussion points between patients and clinicians, which I think focuses on several of the high-level points that one can emphasize in making these decisions, ranging on things from: what are the goals of the treatment? What are the risks and benefits to any one approach? What are comorbidities that should be factored in? Common concerns, toxicity management, clinical trial consideration. All of these factors that I think are incredibly important in making that frontline treatment decision and implementing a regimen that both the clinician and, more importantly, the patient feels comfortable with. Brittany Harvey: It is really important that there is shared decision-making in these scenarios. And I think that patient-clinician communication section can tease out some of those preferences from the patient end and talk through the risks and benefits of different regimens as well. As we mentioned at the top of this episode, this guideline is a living guideline and updated on an ongoing basis. So what is the panel examining and keeping an eye on for future updates to this guideline? Dr. Joshua Reuss: So I think there are a lot of exciting new therapies and more up-to-date trials that we are anxiously awaiting the results of on our committee, and I think the oncology community in general is awaiting the results of. When we will have these results, I think, is a bit of an open-ended question, but I can give some insight on several of the trials that our committee is really keeping a close eye on. One that we have mentioned for several guideline iterations is the ECOG-ACRIN INSIGNA trial. This is a phase III clinical trial comparing pembrolizumab versus pembrolizumab plus carboplatin and pemetrexed chemotherapy in PD-L1 positive, non-squamous, non-small cell lung cancer. We talk about there being different regimens that can be considered in PD-L1 positive and PD-L1 high subsets, namely immunotherapy alone or immunotherapy plus chemotherapy, but there is no direct head-to-head comparison here. So this trial hopefully will answer that question. It has now finished accrual. There are other very interesting molecules and trials. I think another interesting compound is ivonescimab. This is a PD-1/VEGF bispecific antibody that is currently approved in China as monotherapy in patients with PD-L1 positive non-small cell lung cancer based off of the HARMONi-2 trial, where the progression-free survival of this bispecific antibody, ivonescimab, appeared superior to pembrolizumab. And we are looking closely at ongoing trials to see if these results will be replicated in an ex-China population. And if so, I think it could have a real impact and change on our guidelines. Still other very interesting things. There are obviously confirmatory studies for antibody-drug conjugates, such as the TeliMET study that I alluded to earlier, and many promising antibody-drug conjugates, both bispecific and trispecific antibody-drug conjugates, that hopefully can inform practice. And then there are several unique subsets of populations that I think we now are utilizing data on to make decisions, but a lot of that is retrospective in small subsets where we do not have that prospective data. And there are several trials ongoing in some of these subsets to try to gain clarity on what regimen may be the best for patients. One example is the phase III TRITON trial, which is looking at comparing CTLA-4 containing regimen, particularly the POSEIDON regimen of durvalumab plus tremelimumab and chemotherapy, versus the KEYNOTE-189 regimen, which is pembrolizumab plus carboplatin and pemetrexed, in patients with non-squamous, non-small cell lung cancer that have alterations in either KRAS, KEAP1, and/or STK11. There is a lot of both preclinical and clinical data to suggest that patients with these alterations in STK11 and KEAP1 may be more resistant to a PD-1 based treatment approach, and perhaps the incorporation of CTLA-4 can lead to a more meaningful response in this unique subset. Obviously, that data, it is retrospective, it is in small subsets. And when you add in a CTLA-4 molecule, you are also introducing greater risk for toxicity. So this trial is going to be very important in elucidating: is there a benefit in that unique subset? Does that data that we see retrospectively in this small subset hold true when evaluated in a prospective fashion? So while our guideline, our most recent comprehensive panel update, may not have had a lot of new data in it that has influenced frontline treatment decision-making, I think the future is bright and there are a lot of novel studies and novel treatments on the horizon that will hopefully improve the outcomes for our patients. Brittany Harvey: Absolutely. We will look forward to the results of those ongoing trials to provide more options and particularly clarity for patients with non-small cell lung cancer and to inform this guideline and its many updates to come. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Reuss. Dr. Joshua Reuss: Thank you so much. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines App available in the Apple App Store or the Google Play Store. If you have enjoyed what you have heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

The fellas are back and in grand fashion covering everything with the week between the NFL in mind: coaching hires, big moves, previewing the offseason and where do the losers of the conference championship go from here?

In this episode of The EV Musings Podcast, Gary discusses the impact of cold weather on electric vehicles, focusing on battery performance, heating solutions, and practical tips for driving in winter conditions.He explains how cold temperatures affect battery chemistry, leading to reduced range, and offers insights into efficient heating methods, including the use of heat pumps and heated accessories.The episode concludes with essential tips for maximising EV performance in cold weather.The EV Musings Podcast is sponsored by Zapmap, the go-to app for EV drivers, helping you find and pay for public charging with confidence.Links in the show notes:Range test: How far can electric cars go in winter?Episode produced by Arran Sheppard at Urban Podcasts: https://www.urbanpodcasts.co.uk(C) 2019-2026 Gary ComerfordSupport me: Patreon Link: http://www.patreon.com/evmusingsKo-fi Link: http://www.ko-fi.com/evmusingsThe Books:'So, you've gone electric?' on Amazon : https://www.amazon.co.uk/dp/B07Q5JVF1X'So, you've gone renewable?' on Amazon : https://amzn.to/3LXvIckSocial Media:EVMusings: Twitter https://twitter.com/MusingsEvInstagram: @EVmusingsOctopus Energy referral code (Click this link to get started) https://share.octopus.energy/neat-star-460Upgrade to smarter EV driving with a free week's trial of Zapmap Premium, find out more here https://evmusings.com/zapmap-premiumMentioned in this episode:ZapmapThe EV Musings Podcast is sponsored by Zapmap, the go-to app for EV drivers, helping you find and pay for public charging with confidence. Zapmap is free to download and use, with subscription plans for enhanced features such as using Zapmap in-car on CarPlay or Android Auto, and discounted charging across thousands of charge points. Download the app from the Apple App Store or Google Play Store or find out more at www.zapmap.com.Zapmap EV GuideGlobal Women in EV DayThis episode is supported by Global Women in EV Day, an international movement founded by Gill Nowell to celebrate and accelerate the women driving the EV transition. Launching globally on 10 February 2026, the campaign brings the sector together around visibility, equity and action. More info: gillnowell@hostedbygill.co.ukGlobal Women in EV Day

We've all made New Year's resolutions before, right? Right? Okay, not all of us. But at least 3 out of 4 Geek Salad members at least remember making a resolution at some point in the past. So to chat about some of those and just kick off the new year in general, they give you episode 263: Resolve to Resolve My New Year's Resolutions. Join Andy, Mike, Joe, and Katherine as they talk about New Years past, present, or yet to come. How many resolutions have they made and kept versus made and completely forgot about a week later? And what do they have planned for the upcoming 12 months? Geek Salad is available at www.geeksalad.podbean.com, or can be subscribed to at the iTunes store by using keyword “geek salad.”  Geek Salad is also available on Spotify,iTunes,  iHeart Radio and wherever else you get your podcasts! Also, check out the Podbean App where you can stream and download the entire Geek Salad archive right from your Android or iPhone!  You can get the app at either the Google Play Store or the Apple App Store!  Want Geek Salad swag?  Check out our new store on Tee Public, where you can get t-shirts, mugs, stickers, and so much other stuff!!!  Shop here! Geek Salad episodes are now also available to stream on YouTube.  “Like” and Subscribe to their channel at Geek Salad Podcast at www.youtube.com Contact Geek Salad at geeksaladradio@gmail.com.  Geek Salad is also available on Facebook under the group heading “Geek Salad Podcast.” Check out their website at www.geek-salad.com, and please subscribe to their Blue Sky feed: @geeksaladradio Geek Salad is intended for adult listeners and contains coarse language and profanity.  Listener discretion is advised.

Bill Reno is back with a new season of  "Gloves Off" where he takes an unfiltered look at the game with candid conversations w/ former GK's.  This week Bill is joined by Dynasty GK Founder & Former USWNT WC Winning GK Tracy Noonan. The Two discuss her college career, the state of USWNT, and how she's paying it forward to the next generation with Dynasty GK.   Send your comments or questions - contact@insidethe18media.com Video Link -https://www.theunionsports.com/feeds/2487937 More Info on All our shows at www.theuniongk.com *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union!   Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

When overhead is high, you buy cheaper supplies. But there's a better way! In this episode, Kirk Behrendt brings back Ariel Siegel, one of ACT's amazing coaches, to continue the series on overhead and break down supplies percentage. She shares why your numbers may be high, how that impacts your practice, and what you can do about it. For the treatment plan to reduce waste and overspending on supplies, listen to Episode 1000 of The Best Practices Show!Learn More About Ariel:Send Ariel an email: ariel@actdental.com Follow Ariel on ACT's Instagram: https://www.instagram.com/actdentalSend Courtney an email to learn more about ACT: courtney@actdental.com More Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store: https://play.google.com/store/apps/details?id=com.actdental.join&hl=en_USJoin ACT's To The Top Study Club: https://www.actdental.com/tttGet The Best Practices Magazine for free: https://www.actdental.com/magazinePlease leave us a review on the podcast:...

We had a kwentuhan with G Delivers last Philippine Startup Week 2025!G Delivers is your All-in-One Delivery & Transport App! Get food, pharmacy items, groceries, shop essentials, parcels, e-commerce orders, all in one app. Download now on Google Play Store! About to launch in App Store!This episode is recorded live at the Philippine Innovation Hub in Marikina City.In this episode:00:00 Introduction02:33 Ano ang G Delivers?How can listeners find more information?G DELIVERSWebsite: https://g-delivers.comFacebook: https://facebook.com/gdeliversphilippinesPHILIPPINE STARTUP WEEKWebsite: https://phstartupweek.comFacebook: https://facebook.com/PhilippineStartupWeekTHIS EPISODE IS CO-PRODUCED BY:Kredit Hero: ⁠⁠⁠https://kredithero.com/⁠⁠⁠Yspaces: ⁠⁠⁠https://knowyourspaceph.com⁠⁠⁠Twala: ⁠⁠⁠https://twala.io⁠⁠⁠Symph: ⁠⁠⁠https://symph.co⁠⁠⁠Secuna: ⁠⁠⁠https://secuna.io⁠⁠⁠SkoolTek by Edfolio: ⁠⁠⁠https://skooltek.co⁠⁠⁠MaroonStudios: ⁠⁠⁠https://maroonstudios.com⁠⁠⁠CompareLoans: ⁠⁠⁠http://compareloans.ph⁠⁠⁠CHECK OUT OUR PARTNERS:Ask Lex PH Academy: ⁠⁠⁠https://asklexph.com⁠⁠⁠ (5% discount on e-learning courses! Code: ALPHAXSUP)ArkoTech: ⁠⁠⁠https://www.arkotechspacesolutions.com/⁠⁠⁠DVCode Technologies Inc: ⁠⁠⁠https://dvcode.tech⁠⁠⁠NutriCoach: ⁠⁠⁠https://nutricoach.com⁠⁠⁠Argum AI: ⁠⁠⁠http://argum.ai⁠⁠⁠PIXEL by Eplayment: ⁠⁠⁠https://pixel.eplayment.co/auth/sign-up?r=PIXELXSUP1⁠⁠⁠ (Sign up using Code: PIXELXSUP1)School of Profits: ⁠⁠⁠https://schoolofprofits.academy⁠⁠⁠Founders Launchpad: ⁠⁠⁠https://founderslaunchpad.vc⁠⁠⁠Hier Business Solutions: ⁠⁠⁠https://hierpayroll.com⁠⁠⁠Agile Data Solutions (Hustle PH): ⁠⁠⁠https://agiledatasolutions.tech⁠⁠⁠Smile Checks: ⁠⁠⁠https://getsmilechecks.com⁠⁠⁠CloudCFO: ⁠⁠⁠https://cloudcfo.ph⁠⁠⁠ (Free financial assessment, process onboarding, and 6-month QuickBooks subscription! Mention: Start Up Podcast PH)Cloverly: ⁠⁠⁠https://cloverly.tech⁠⁠⁠BuddyBetes: ⁠⁠⁠https://buddybetes.com⁠⁠⁠HKB Digital Services: ⁠⁠⁠https://contakt-ph.com⁠⁠⁠ (10% discount on RFID Business Cards! Code: CONTAKTXSUP)Hyperstacks: ⁠⁠⁠https://hyperstacksinc.com⁠⁠⁠OneCFO: ⁠⁠⁠https://onecfoph.co⁠⁠⁠ (10% discount on CFO services! Code: ONECFOXSUP)Wunderbrand: ⁠⁠⁠https://wunderbrand.com⁠⁠⁠Uplift Code Camp: ⁠⁠⁠https://upliftcodecamp.com⁠⁠⁠ (5% discount on bootcamps and courses! Code: UPLIFTSTARTUPPH)START UP PODCAST PHYouTube: ⁠⁠⁠https://youtube.com/startuppodcastph⁠⁠⁠Spotify: ⁠⁠⁠https://open.spotify.com/show/6BObuPvMfoZzdlJeb1XXVa⁠⁠⁠Apple Podcasts: ⁠⁠⁠https://podcasts.apple.com/us/podcast/start-up-podcast/id1576462394⁠⁠⁠Facebook: ⁠⁠⁠https://facebook.com/startuppodcastph⁠⁠⁠Patreon: ⁠⁠⁠https://patreon.com/StartUpPodcastPH⁠⁠⁠PIXEL: ⁠⁠⁠https://pixel.eplayment.co/dl/startuppodcastph⁠⁠⁠Website: ⁠⁠⁠https://phstartup.online⁠⁠⁠This episode is edited by the team at: ⁠⁠⁠https://tasharivera.com⁠⁠

Success isn't just about the medals. In this episode, Kirk Behrendt brings back Dr. Amanda Seay, president of the AACD, and Dr. Zach Sisler, board chair of the AACD, to share their journeys and lessons of the accreditation process and the importance of investing in yourself for your future. To learn what success could look like for you, listen to Episode 999 of The Best Practices Show!Learn More About Dr. Seay & Dr. Sisler:Join Dr. Seay on Facebook: https://www.facebook.com/DrAmandaSeayFollow Dr. Seay on Instagram: https://www.instagram.com/dramandaseayJoin Dr. Sisler on Facebook: https://www.facebook.com/SmilesBySislerFollow Dr. Sisler on Instagram: https://www.instagram.com/dr_zachsislerRegister for the AACD Scientific Session (April 16-18, 2026): https://www.aacdconference.com/event/1a1b9fe4-2097-4006-b107-822d4da3654b/main-menuMore Helpful Links for a Better Practice & a Better Life:Subscribe to The Best Practices Show: https://the-best-practices-show.captivate.fm/listenJoin The Best Practices Association: https://www.actdental.com/bpaDownload ACT's BPA app on the Apple App Store: https://apps.apple.com/us/app/best-practices-association/id6738960360Download ACT's BPA app on the Google Play Store:

I18 GK Podcast is proud to present a very special conversation with US Soccer's Head of Goalkeeping Jack Robinson.  The crew chat how to develop a nat gk program, how to build a goalkeeper pool in a country of such scale, and how US Soccer is paving the way for cultural gk exchange from grassroots all the way to the professional game!  Great listen for young coaches, players and parents!! Download the Union GK community on Apple or Google Play Stores for more! Video Link Here - https://www.theunionsports.com/feeds/2491611 *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union! Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises for players to fine-tune technical and tactical awareness. Pro Analysis Tools: Receive insightful feedback on past performance from expert coaches to elevate your game. Mindset and Performance Coaches: Access to coaches specializing in mental toughness in soccer players. Access to help to boost self-esteem, conflict resolution with coaches and players, and mindset. The Gift That Keeps Them in the Game! Your Premium Subscription to The Union Goalkeeper App offers easily accessible tools at the low yearly cost of $49.99 - Subscribe now for the year, and you'll receive an exclusive UNION GK premium hat (retail value $25.00)! Use code HOLIDAYGWP at checkout. Don't miss out – Keeperstop Coupon Code:  Union GK members can save an additional 10% with code:  UGK23.  Contact the goalkeeper equipment experts in the USA for goalkeeper gloves and equipment.  Always always available to answer any sizing or equipment question. Don't forget to sign up for office Hours on the Union GK App Portal https://www.theunionsports.com/office_schedulers?k=c1a46a8b Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Happy New Year! I18 GK Podcast is back for 2026!  99WC Winner Saskia Webber and Comedian Michael Magid are joined by The TKI Podcast and Gloves OFF Crew continue their debate and bracket breakdown of the Final 4 Schools and crown our GKU!   64 Team Bracket avail online .  Great listen for young coaches, players and parents!! Download the Union GK community on Apple or Google Play Stores for more! Video Link Here - https://www.theunionsports.com/feeds/2491611 *If you want us to come to your town; all you've got to do is DM us @goalkeeperpodcast on The Union & tell us what you've got in mind. The Following is a FREE Preview of the popular Inside The 18 Goalkeeper Podcast. Want to continue watching or listening? Then Join a 30 day free trial of The Union GK App the new exclusive home of  the pod. For more info; go to www.theuniongk.com ; or download the The Union GK Community on Apple or Google Play Stores. Thanks for all your support & we'll see you on The Union! Unlock Excellence with UNION GK APP Premium Features: One-On-One Virtual Coaching Sessions: Meet with world-class coaches and goalkeepers to discuss your performance, technical assessments, the college recruiting process, and more. Personalized Training Plans: Access to tailored training plans designed by professional goalkeepers to enhance skills and understanding of the position. Exclusive Drills Library: Unlimited access to the Union GK's goalkeeping drills and exercises for players to fine-tune technical and tactical awareness. Pro Analysis Tools: Receive insightful feedback on past performance from expert coaches to elevate your game. Mindset and Performance Coaches: Access to coaches specializing in mental toughness in soccer players. Access to help to boost self-esteem, conflict resolution with coaches and players, and mindset. The Gift That Keeps Them in the Game! Your Premium Subscription to The Union Goalkeeper App offers easily accessible tools at the low yearly cost of $49.99 - Subscribe now for the year, and you'll receive an exclusive UNION GK premium hat (retail value $25.00)! Use code HOLIDAYGWP at checkout. Don't miss out – Keeperstop Coupon Code:  Union GK members can save an additional 10% with code:  UGK23.  Contact the goalkeeper equipment experts in the USA for goalkeeper gloves and equipment.  Always always available to answer any sizing or equipment question. Don't forget to sign up for office Hours on the Union GK App Portal https://www.theunionsports.com/office_schedulers?k=c1a46a8b Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.